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Acute myeloid leukemia (AML) is a malignant neoplasia of the blood system 
and can occur in people at all ages but more frequently affects people older 
than 65 years. Although the outlook for patients with AML has improved 
over the past decades, still more than half of young adult and about 90% of 
elderly patients die from their disease. The main obstacles to cure are refrac-
toriness to initial induction treatment and, more frequently, relapse after ap-
parent remission. From a cellular perspective, relapse is thought to occur from 
rare cell populations of so-called “leukemia stem cells” (LSCs) which share 
molecular and functional features with their healthy counterparts, the hema-
topoietic stem cells (HSCs). Because they underlie complex regulatory mech-
anisms, particularly also involving other cell types and niches, LSCs need to 
be studied in vivo. For human LSCs, such studies are confined to xenotrans-
plantation models, which usually are performed in immunosuppressed mice. 
In this thesis, a better understanding of human AML was built up by (1) es-
tablishing and improving a stable xenotransplantation model, (2) by identify-
ing a novel LSC marker based on the concept of immune escape and (3) by 
unraveling novel non-cell autonomous pro-leukemogenic mechanisms in-
volving BM niche and healthy hematopoietic stem and progenitor cells 
(HSPCs) modulation by CDX2 expressing leukemic cells. Lastly, we use an ex 
vivo 3-dimensional niche surrogate for expansion of healthy HSPCs. 
Firstly, an improved transplantation protocol of human AML cells into im-
munosuppressed NOD/SCID/IL2Rγnull (NSG) mice that mimics the clinical 
course of the disease in patients was established. In this model, the latency of 
AML cell engraftment in mice depends on molecular risk groups established 
in patients and xenogeneic leukemic cells show conserved genetic and pheno-
typic features. Most importantly, the model enables the engraftment of favor-
able risk AML subtypes previously considered non-engraftable in NSG mice, 
opening up new perspectives for in vivo studies on these disease subtypes. We 
further optimized this model by observing that transplantation at night or 
under enhanced catecholamine activity favors homing and adhesion of leu-
kemic cells to BM niches, thereby shortening time-to-leukemia in vivo.  
Next, this model was used for mechanistic in vivo studies on leukemia initia-
tion. In close collaboration with the immunology research group led by Prof. 
Helmut Salih (University of Tuebingen, Germany), NKG2D-associated im-
mune privilege was identified as a feature of human AML LSCs. These find-
 ix 
ings offer a novel method for LSC isolation in several subtypes of AML and 
demonstrate in functional assays an unrecognized and targetable mechanism 
for sensitizing LSCs to immune control.  
Furthermore, our studies on the transcription factor CDX2, which is ex-
pressed in >80% of AML but not detectable in healthy HSPCs, unraveled a 
novel non-cell-autonomous role by which CDX2 promotes leukemogenesis, 
namely via DKK1 secretion to outcompete resident healthy HSPCs, which in-
dicates treatment with WNT agonists as potential strategy to treat incipient 
AML (e.g. AML at minimal residual disease stage). 
Last, as part of a collaborative project with the research group led by Prof. 
Ivan Martin (Department of Biomedicine, University of Basel), an ex vivo BM 
niche surrogate system was analyzed for its potential to expand and analyze 
healthy cord-blood derived HSPCs in vitro, which could also be adapted to 
recapitulate pathological situations as leukemia. This could represent a pow-
erful tool with wide range of applications, from the identification of factors 
deregulating niche or blood functions, to the screening of drugs to predict pa-
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2.1 “Long-term observation reveals high-frequency engraftment of 
human acute myeloid leukemia in immunodeficient mice” 
In this publication, I performed and designed all experiments except for the 
immunohistochemistry (performed by Stephan Dirnhofer) and the next gen-
eration sequencing (performed by P. Lundberg). I analysed the data with the 
help of Stephan Dirnhofer, Martina Konantz, Pontus Lundberg and Claudia 
Lengerke. Michael Medinger, Helmut R. Salih, Kathrin Rothfelder, Dimitrios 
A. Tsakiris and Jakob R. Passweg contributed patient samples or critical rea-
gents. Martina Konantz provided critical input to the manuscript and critical 
help with the design of the figures. Claudia Lengerke and I conceived and 
developed the study and methodology and wrote the manuscript.  
 
2.2 “Absence of NKG2D ligands defines human leukaemia stem 
cells and mediates their immune evasion” 
I designed and performed all functional experiments involving in vitro and in 
vivo treatments of human AML cells and subsequent analysis of NKG2DL ex-
pression (shown in Figures 2 and 4, Extended Data Figures 8, 9, 10, 13, 17 and 
19, as well as Supplementary Figures 6-7 of the manuscript), with exception of 
the in vitro 5-azacytidine treatments shown in Extended Data Figure 10a 
which were performed by Kathrin Rothfelder at the University of Tuebingen. 
Furthermore, I performed the in vitro colony forming assays and the morpho-
logical analyses with sorted human AML cells as well as further phenotypic 
characterization regarding LSC markers (shown in Figures 1, 2 and 3, Extend-
ed Data Figures 2, 3, 6 and Supplementary Figure 5) and all in vivo experi-
ments shown in Figures 1-4, Extended Data Figures 8, 13 and 19, as well as 
Supplementary Figure 1 and 5. Of note, NK cells used in the experiments 
shown in Figures 2 and 4 were generated in Tuebingen by Kathrin Rothfelder 
and then transported to Basel to be used in experiments. Simon Raffel and 
Mattia Falcone performed RNAseq analyses shown in Figure 1q and 4a, Si-
mon Raffel, and Eva Nievergall performed the in vivo experiments shown in 
Supplementary Figure 2 and in part in Figure 1i (only for BM). The Western 
blots were performed by Hui Wang and Thorsten Schaefer after I performed 
the cell sorting into NKG2DLpos and NKG2DLneg cells. For the microarray 
analyses AML cells sorted by Julia Steinbacher and me were used and analy-
sis performed by the company IMGM. Kathrin Rothfelder performed analyses 
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of NKG2DL expression in the AML cohort, performed experiments involving 
NK cell generation, 5-azacytidine treatments, shedding analysis and collected 
clinical data on the patients together with Daniela Dörfel and Claudia Tandler 
and performed statistical analyses on associations between NKG2DL expres-
sion and patient’ characteristics. Martina Konantz contributed to the bioin-
formatical analysis on gene expression and RNAseq data sets, performed 
qRT-PCR experiments together with Hui Wang. Pontus Lundberg performed 
the next generation sequencing analysis. Helmut R. Salih, Lothar Kanz, Chris-
toph Lutz provided access to clinical samples and purified cells. Leticia Quin-
tanilla-Martinez performed mouse histopathological analyses. Alexander 
Steinle provided critical reagents for NKG2DL analysis. Data analysis was 
performed by me, Kathrin Rothfelder, Simon Raffel, Martina Konantz, Julia 
Steinbacher, Hui Wang, Thorsten Schäfer, Daniela Dörfel, Mattia Falcone, 
Pontus Lundberg, Leticia Quintanilla-Martinez, Helmut Salih and Claudia 
Lengerke. The figures were designed by me and Martina Konantz, with the 
help of Kathrin Rothfelder, Simon Raffel, Helmut Salih and Andreas Trumpp. 
Andreas Trumpp contributed to the study design and co-supervised the 
study. The study was conceived and supervised, and the manuscript written 
by Claudia Lengerke (as led author) and Helmut Salih. All authors critically 
reviewed the manuscript. 
 
2.3 “Biometric engineering of a functional ex vivo human hemato-
poietic niche” 
In this project I designed, performed as well as analysed the in vivo mouse ex-
periments. Paul E. Bourgine, Thibaut Klein and Ivan Martin conceived the 
study. Paul E. Bourgine, Thibaut Klein, Takafumi Shimizu, Leo Kunz, Kon-
stantinos D. Kokkalliaris, Daniel L. Coutu and I analysed the data. Paul E. 
Bourgine, Timm Schroeder, Ivan Martin and Thibaut Klein wrote the manu-
script and I helped with proofreading. Timm Schroeder, Ivan Martin, Radek 










3.1 Human Acute Myeloid Leukemia  
3.1.1 Clinical perspective 
Acute myeloid leukemia (AML) is defined as malignant disease of hemato-
poietic stem and/or progenitor cells (HSPCs) of the myeloid lineage character-
ized by uncontrolled proliferation and accumulation of leukemic blasts in the 
bone marrow (BM), peripheral blood (PB) and other organs (Ferrara and 
Schiffer, 2013; Greim et al., 2014). AML is the most common type of acute leu-
kemia in adults and can occur at all ages but affects more frequently elderly 
people, where it mainly progresses with an aggressive clinical course 
(Herrmann et al., 2012; Juliusson et al., 2009; Mrózek et al., 2012). Although 
the outlook for patients with AML has improved over the past decades, still 
more than half of young adults and about 90% of elderly patients die from 
their disease. The main challenges to cure AML are the missing response to 
initial induction therapy and, more frequently, relapse after first remission 
(occurring from low numbers of leukemic cells able to survive chemotherapy, 
the so-called leukemic stem cells) (Ferrara and Schiffer, 2013). If no therapy is 
given to AML patients, this leads to death which may result from infection, 
bleeding or organ infiltration (Gutierrez and Romero-Oliva, 2013). From a 
molecular perspective, AML is a heterogeneous disease, showing a great ge-
netic and phenotypic variety (Faber et al., 2013). Genes found mutated in 
AML are grouped in three classes: (1) genes that confer growth advantages by 
activating downstream effectors of various signaling pathways (e.g. RAS), (2) 
genes that impair differentiation by modulating expression of key transcrip-
tional targets (e.g. RUNX1, MLL) and (3) a third category comprising muta-
tions in genes thought to act via epigenetic mechanisms (e.g. DNMT3A), 
which has been added more recently. A significant amount of AML cases is 
associated with nonrandom chromosomal translocations, the most common 
being t(15;17)/PML-RARα, t(8;21)/AML1-ETO, inv(16)/core binding factor 
(CBF)b-MYH11, 11q23 and mixed lineage leukemia (MLL)-fusion proteins as 
well as FLT3-ITD (Mrózek et al., 2012). The molecular background strongly 
affects outcome and clinical prognosis in AML, which is however furthermore 
dependent on patient-related factors (e.g. age, fitness and comorbidities af-
fecting treatment choice) (Herrmann et al., 2012).  
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3.1.2 AML characteristics and classification 
Molecular and cytogenetic criteria have been shown to predict AML aggres-
siveness in patients. The European LeukaemiaNet (ELN) uses these for the 
classification of adult AML into favorable, intermediate and adverse risk 
groups (Döhner et al., 2017). The French-British-American (FAB) classification 
further categorizes AML according to morphological criteria. Analyses corre-
lating molecular characteristics with patient survival resulted in the definition 
of molecular favorable, intermediate and poor risk groups that can predict 
survival (Figure 1) (Mrózek et al., 2012). Of note, there are also survival dif-
ferences between younger and elderly patients of the same ELN molecular 
risk group (Figure 1A younger and Figure 1B elderly patients) (Mrózek et al., 
2012). These are on the one hand due to patient-related factors (e.g. lower tol-
erance of intensive chemotherapy and higher transplant-related adverse ef-
fects in elderly compared to younger patients due to more advanced age 
and/or comorbidities). But on the other hand perhaps also due to disease-
specific differences, since in elderly patients AML initiates in more aged, and 
perhaps genetically pre-damaged and instable HSPCs, and evolves in close 
interaction with a more aged microenvironment and immune system (Silva et 




      
Figure 1: Molecular risk group classification predicts human AML aggressiveness in pa-
tients. Probability of patient survival stratified by ELN molecular risk group in younger 
(<60y; A) and elderly (>60y; B) patients (Mrózek et al., 2012). 
 
Importantly, this molecular classification directs the treatment choice (Döhner 
et al., 2017; Medinger et al., 2016a; Medinger et al., 2016b, c; Nagel et al., 2017): 
to achieve cure, patients with favorable risk AML e.g. receive intensive chem-
otherapy alone. Intermediate or adverse risk AML patients are at higher risk 
for relapse with such therapies and, whenever possible, additionally receive 
stem cell transplantation – which leads to enhanced therapy-related mortality 
and morbidity. 
Although molecular criteria have significantly improved prognostication and 
therefore also AML patient stratification and risk-based treatment, a full risk 
prediction is still not available. Further parameters are needed to better strati-
fy patients and personalize treatment towards a targeted therapy for each pa-
tient. Especially within the intermediate risk group, which represents ~40-50% 
of de novo AML (Mrózek et al., 2012), there is high variability with respect to 




3.1.3 Leukemia stem cells and the hallmarks of cancer 
The cancer stem cell (CSC) hypothesis postulates the existence of a subpopu-
lation within each neoplasm, the cancer stem cells, which possess both the 
ability to undergo self-renewal and to differentiate into all types of cells re-
constituting the heterogeneity of the original tumor. Furthermore, CSCs are 
considered to better survive chemotherapy and lead to subsequent relapse 
(Hanahan and Weinberg, 2000, 2011). Therefore, further characterization of 
CSC compartments and identification of targeted therapies capable to kill 
CSCs, not only mature tumor cells, has been proposed as major research goal. 
Thus, the oncogenic transformation leading to the generation of malignant 
self-renewing cells, the so-called leukemic stem cells (LSCs), is one key event 
in leukemogenesis. In AML, a hierarchical organization was described among 
malignant cells: on the one hand, there are more mature cells that undergo 
apoptosis after a variable number of cell divisions and on the other hand, 
there are immature primitive cells with self-renewing and leukemia propagat-
ing capacity (Bonnet and Dick, 1997; Herrmann et al., 2012; Hope et al., 2004; 
Lapidot et al., 1994; Schulenburg et al., 2010).  
 
3.1.3.1 Classical LSC markers 
Several studies focused on the identification of CSC markers in different tu-
mor entities including solid tumors and leukemias. In AML, for example, this 
is very challenging since most of these antigens are also broadly expressed on 
various mesenchymal and healthy hematopoietic stem and progenitor cells 
(HSPCs). While the exact phenotype of LSCs in AML remains still unclear, 
several studies suggested that the LSC population resides within the 
CD34+CD38- fraction (Eppert et al., 2011; Herrmann et al., 2012; Lapidot et al., 
1994). One of the first studies to further restrict the phenotype identified 
CD44, an adhesion molecule that binds selectins and hyaluronic acid, as ex-
pressed in AML stem cells where it mediates homing, engraftment and LSC 
maintenance (Jin et al., 2006). Unfortunately, CD44 expression is also found 
on hematopoietic and non-hematopoietic stem cells, mature blood cells like 
monocytes, granulocytes and lymphocytes, epithelial cells and melanocytes, 
making it difficult to specifically distinguish and target LSCs. This is also the 
case for CD34 expression, which is not only found on HSCs but also on more 
mature progenitors as well as for example classically on endothelial cells 
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(Schulenburg et al., 2010). More recently, GPR56 was found to be expressed 
on LSCs, but not their more differentiated non-LSC counterparts in human 
AML (Pabst et al., 2016; Saito et al., 2013) and in a murine leukemia model 
(Daria et al., 2016). More markers proposed to further enrich LSCs within 
CD34+CD38- populations are CD123 (IL-3 receptor alpha chain) (Jin et al., 
2009), CD25 (IL-2 receptor alpha-chain) (Saito et al., 2010), CD96 (Hosen et al., 
2007), CD47 (Majeti et al., 2009), CLL-1 (van Rhenen et al., 2007), CD99 
(Chung et al., 2017) or TIM3 (Jan et al., 2011). Of note, in these studies markers 
have been characterized on top of CD34+CD38- populations as pre-
enrichment. Importantly, it has also been demonstrated that in CD34 non-
expressing AML only subpopulations of leukemic cells have stem cell proper-
ties, however in this particular subtype, no reliable marker has been yet iden-
tified (Quek et al., 2016; Taussig et al., 2010). 
Taken together, no leukemic stem cell specific antigen that holds true for all 
samples has been identified in AML so far, and especially in CD34 non-
expressing AML (which correspond to ~30% of all AML) LSC markers remain 
elusive. 
 
3.1.3.2 LSCs and immune escape 
In their up-dated version from 2011, Hanahan & Weinberg described immune 
evasion as an emerging hallmark of cancer (Hanahan and Weinberg, 2011). 
The interactions between cancer stem cells and the immune system are how-
ever under-explored although some recent reports indicate that tumor stem 
cells may possess specific mechanisms of immune escape. For example, acti-
vated peripheral blood mononuclear cells (PBMCs) from patients with mela-
noma were shown to more efficiently inhibit tumor non-stem than stem cells 
via selective induction of immunosuppressive IL-10 and inhibition of stimula-
tory IL-2 (Schatton et al., 2010). Glioblastoma stem (but not non-stem) cells 
likely inhibited T cell proliferation via secretion of IL-2 and IFN-γ (Wei et al., 
2010) and enhanced apoptosis of tumor-infiltrating lymphocytes via PD-L1 
(programmed death ligand 1) (Dong and Chen, 2003; Hirano et al., 2005; Wei 
et al., 2010). In colorectal carcinoma, higher resistance towards γδ T cell lysis 
was described in stem versus non-stem cells (Todaro et al., 2009). Finally, 
down-regulation of the MHC class I was reported as a mechanism impairing 
T cell recognition of melanoma and respectively glioma stem cells (Di Tomaso 
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et al., 2010; Schatton et al., 2010). According to the so-called “missing self-
hypothesis”, down-regulation of MHC class I expression would make these 
cells more amenable to NK (natural killer) cell lysis. However, NK cell activa-
tion also requires stimulation via activating NK cell receptors (“induced self”) 
such as NKG2D: NKG2D receptors on NK cells interact with NKG2D ligands 
(NKG2DL) on target cells that here are induced by exposure to cell stress, vi-
ral infection or tumorigenic transformation (Lanier, 2001; Vivier et al., 2008). 
Expression of NKG2DL on target cells then enables their recognition and sub-
sequent lysis by NK cells. In contrast, down-regulation of NKG2DL allows 
cells to escape NK cell-mediated immune surveillance. Perhaps reflecting the 
complex regulatory interactions between tumor (stem) and NK cells, contra-
dictory results have been reported on tumor stem cell recognition by NK cells. 
Ames et al. e.g. report preferential NK cell mediated lysis of cancer cells carry-
ing a stem cell phenotype in a limited number of sarcoma and pancreas carci-
noma samples and one breast carcinoma cell line (Ames et al., 2015). Howev-
er, Reim et al. showed preferential survival of CD44(high)CD24(low) putative 
breast carcinoma stem cells after co-culture with NK cells, suggesting that 
they selectively escape NK cell attack (Reim et al., 2009).  
 
3.2 Mouse models 
3.2.1 Xenotransplantation models of hematopoietic cells 
Healthy hematopoietic and also leukemic cells pursue complex interactions 
with other cell types making their study in an in vivo context mandatory. This 
is particularly evident in the hematopoietic system where HSPCs are tightly 
regulated by extrinsic signals since they need to rapidly differentiate upon 
demand in different functional blood cells (Goulard et al., 2018). Furthermore, 
HSCs need to sustain hematopoiesis throughout the life spam of an organism 
and therefore suppress excessive differentiation and cycling that can lead to 
exhaustion and facilitate DNA damage (Rossi et al., 2007). Because of the 
complex fine-tuned mechanisms regulating their quiescence, self-renewal and 
differentiation, HSCs – and also their malignant counterparts, the LSCs – are 
notoriously hard to cultivate and to expand in vitro (Morrison and Scadden, 
2014; Schofield, 1978, 1983). In fact, most AML cells cultured in vitro undergo 
spontaneous cell death within a few days of culture making in vivo studies 
mandatory for longer-term assays and investigations on LSC identity.  
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Animal models (e.g. mice) are intensively used for such in vivo studies; how-
ever, mouse models of AML rely on a limited number of defined genetic 
events and often do not fully mimic the heterogeneity observed in primary 
human AML samples. An alternative approach is to study primary human 
cells in vivo by xenotransplantation of these cells into a xenogeneic (e.g. mu-
rine) environment (Lapidot et al., 1994). Over the past decades, many efforts 
have been made to generate most accurate xenotransplantation models in 
which human HSPCs or leukemic cells are successfully engrafted into immu-
nosuppressed mice (Cosgun et al., 2014; Reinisch et al., 2016; Rongvaux et al., 
2014; Sanchez et al., 2009; Shultz et al., 2005; Strowig et al., 2011; Theocharides 
et al., 2012).  
Different animal models have been used as hosts for xenotransplantation of 
human AML cells. First xenotransplantation studies were performed in SCID 
(severe combined immunodeficiency) mice, later in NOD/SCID (non-obese 
diabetic/SCID) lacking B and T cells (Shultz et al., 2005), and finally in 
NOD/SCID/IL2Rγnull (NSG) strains that additionally lack functional NK cells 
(Sanchez et al., 2009). Of these, NSG mice appear to enable most robust en-
graftment rates probably due to their high level of immunosuppression. Alt-
hough human engraftment is successful, these models are still limited by re-
maining macrophages, which have been shown to phagocytize transplanted 
human cells (Theocharides et al., 2012). Additionally, there is only partial 
cross-reactivity between human and murine proteins (especially of cytokines 
required for hematopoiesis) and niche components (Mendelson and Frenette, 
2014). Therefore, more recently, knock-in mice have been generated for hu-
man cytokines (“humanized mice”, e.g. M-CSF, GM-CSF, TPO, SCF, IL-3) 
(Rongvaux et al., 2014) or for the human SIRPA gene, a receptor negatively 
regulating phagocytosis, in the background of immunosuppressed mouse 
strains (Strowig et al., 2011). Moreover, Cosgun et al. demonstrated in 2014 
that introduction of Kit receptor mutations in the background of immunosup-
pressed mouse strains improves the engraftment of human HSPCs by induc-
ing a defect in the endogenous hematopoietic stem cell compartment and 
therefore creating niche space and offering xenotransplanted cells a competi-
tive advantage over endogenous cells (Cosgun et al., 2014). Humanized niche 
scaffold elements have been engineered using human stromal cells and re-
vealed enhanced repopulation with human HSPCs when implanted into im-
munosuppressed mouse strains (e.g. ossicles coated with human mesenchy-
mal stem cells (MSCs), which recently were demonstrated to enhance both 
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human healthy and malignant hematopoietic engraftment) (Reinisch et al., 
2016). 
Among others, these xenotransplantation models have indicated a hierar-
chical organization of human AML with the capacity of leukemia initiation, 
maintenance and relapse being confined to rare subpopulations of so-called 
leukemia initiating-cells (LICs) or leukemic stem cells (LSCs) (Eppert et al., 
2011; Lapidot et al., 1994). In 1994, Lapidot et al. first showed engraftment of 
human primary AML cells in severe combined immuno-deficient (SCID) mice 
and described that LSCs reside in the CD34+CD38- subpopulations within in-
dividual AML samples (Lapidot et al., 1994). More recent comprehensive 
analyses demonstrate high marker heterogeneity between AML samples and 
show that LSCs are often also found in the CD34+CD38+ compartment and al-
so exist as CD34- cells, in so-called CD34 non-expressing AML subtypes 
(Quek et al., 2016; Taussig et al., 2010).  
 
3.2.2 Factors influencing engraftment in the NSG xenotransplanta-
tion model 
Next to differences depending on the used mouse strain, the efficiency of 
xenotransplantation assays of human healthy hematopoietic stem and pro-
genitor cells as well as primary AML cells depends on several factors: 
1. Age of the recipient mice: Usually 6 to 10 week old mice are used for 
xenotransplantation experiments of healthy CD34+ hematopoietic cells. 
Transplantation into newborn mice (up to 3 days after birth) has been 
reported to be more efficient but is logistically more difficult (Traggiai 
et al., 2004).  
2. Gender of recipient mice: Engraftment of healthy human CD34+ cells 
(Notta et al., 2010) and also of human acute lymphoblastic leukemia 
cells (Konantz et al., 2013) is more efficient in female versus male NSG 
recipients.  
3. Transplanted cell dosage and cell source: Unselected AML cells are 
usually transplanted at 0.5-1x106 cells per mouse, while LSCs enriched 
populations are injected at lower numbers (down to 0.5x105 cells). Most 
reports document engraftment from ~40% of transplanted primary 
AML samples (Eppert et al., 2011) and indicate a clear overrepresenta-
 16 
tion of aggressive molecular risk subtypes within the successfully en-
grafted AML samples. Higher engraftment rates (66%) were reported 
using increased numbers of transplanted cells (10x106 per mouse), a 
lower threshold for the definition of human engraftment (>0.1% human 
cells within murine bone marrow (BM), peripheral blood (PB) or or-
gans) (Sanchez et al., 2009), and use of high molecular risk (e.g. FLT3-
ITD mutated) subtypes (Sanchez et al., 2009).  
4. Transplantation method: Intrafemoral (i.f.) (Mazurier et al., 2003) and 
intravenous (i.v.) injections are used for transplantation of human 
AML cells into mice. When transplanted i.f., AML cells are directly 
transplanted into vicinity of the BM niches. Direct injection in the liver 
of newborn mice, a natural site of hematopoiesis amplifying HSCs dur-
ing development, was shown to further enhance HSC engraftment 
(Traggiai et al., 2004). 
5. Pre-conditioning of mice (e.g. irradiation): Sub-lethal irradiation facil-
itates engraftment and is commonly used in most protocols 
(Theocharides et al., 2016). Engraftment without prior irradiation has 
also been reported (e.g. (Klco et al., 2014)) and might be a better option 
for studying niche interactions without destroying or disturbing the 
healthy niche. 
6. Time point of analysis post-transplantation and threshold set to de-
fine engraftment: Mice are mostly considered as successfully engraft-
ed if >1% (in two reports also >0.1% (Sanchez et al., 2009; Shlush et al., 
2014)) of human AML cells are detectable in the PB or the BM of mice. 
Across reports, mice are followed mostly for 12 and no longer than 16 
weeks post-transplantation. 
7. Time-point of injection: Depending on the number of circulating en-
dogenous HSCs, the number of open niches varies, which follows cir-
cadian oscillations (Méndez-Ferrer et al., 2008). Correlations between 
time-point of injection and AML or HSPC cell homing and long-term 
engraftment are not yet reported and were subject of investigation in 
the current thesis. 
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3.2.3 Homing of hematopoietic cells - and the involvement of circadian 
rhythm and catecholamines  
Homing originally describes the ability of HSCs to find their way (“home”) 
into the BM. So far, the SDF1-CXCR4 axis was described as the main molecu-
lar regulator of HSC homing. Further analyses of this axis revealed that it fol-
lows circadian oscillations. In 2008, Méndez-Ferrer and co-workers showed 
that after light exposure, SDF1 protein is released from the BM while SDF1 
mRNA is down-regulated; this leads to higher HSC mobilization and there-
fore enhanced levels of circulating HSCs, showing a peak 5 hours after light 
onset (Méndez-Ferrer et al., 2008). It is possible that enhanced mobilization of 
endogenous HSCs into the circulation might open up niche space and then 
facilitate repopulation with transplanted AML cells and/or HSPCs. Moreover, 
a link between circadian oscillations, SDF1 expression and catecholamines has 
been described. For example, stimulation of β2-adrenergic receptors (ARs) in 
osteoblasts was shown to induce clock gene expression whereas β3-AR activa-
tion results in acute SDF1 mRNA down-regulation, which are compensatory 
mechanisms involved in the above-mentioned circadian mechanism of HSC 
mobilization (Fu et al., 2005; Liu et al., 2007; Méndez-Ferrer et al., 2008).  
Furthermore, Katayama and colleagues described that the sympathetic nerv-
ous system (SNS) supports normal hematopoiesis by regulating HSC egress 
from the BM through the action of catecholamines (Katayama et al., 2006), 
which therefore control the normal BM microenvironment in order to main-
tain a stem cell pool in the BM (Dar et al., 2011). Taken together, catechola-
mines play important roles in regulating hematopoietic hemostasis, but their 
function is not completely understood. In this regard, Spiegel and colleagues 
studied the interplay of catecholamines with the dynamics of human CD34+ 
HSPC engraftment and were able to show that treatment with catecholamines 
indeed enhanced the engraftment in NOD-SCID mice. They explained this 
phenotype by their observations regarding Wnt signaling activation and – at 




3.3 Healthy hematopoiesis 
3.3.1 Blood development and hematopoietic stem cells  
Hematopoiesis, the formation of blood cells, occurs during embryonic devel-
opment, when primitive erythroid and myeloid cells and later on definitive 
HSCs are established from endothelial cells, and then throughout adulthood 
when blood cells are produced to maintain the blood system (Jagannathan-
Bogdan and Zon, 2013). Since mature blood cells have a limited life-span and 
progenitor cells an expanded but eventually limited life-span, HSCs are re-
quired to sustain life-long hematopoiesis (Orkin and Zon, 2008). 
In vertebrates, blood development comprises different waves of hematopoie-
sis. As mentioned above, the primitive wave occurs first and involves 
erythroid and myeloid progenitor cells formed during early embryonic de-
velopment in the extra-embryonic yolk sac (Palis and Yoder, 2001) followed 
by a transient wave in which the so-called erythroid-myeloid progenitors 
(EMPs) are produced (McGrath et al., 2011). Finally, definitive hematopoiesis 
occurs as the last wave of developmental hematopoiesis in which HSCs are 
formed from endothelial cells in the aorto-gonado-mesonephros (AGM) re-
gion of the developing embryo. HSCs then relocate to the fetal liver where 
they undergo rapid expansion, and then, in mouse and humans, shortly be-
fore birth move to the bone marrow (BM) which is the location for HSCs and 
therefore the main site of hematopoiesis in adults (Cumano and Godin, 2007; 
Jagannathan-Bogdan and Zon, 2013; Lengerke and Daley, 2012). In each of 
these sites, HSC properties differ in regard to different niches supporting HSC 
expansion and differentiation and intrinsic characteristics of HSCs at each 
stage. For example, HSCs in the fetal liver are in cycle, whereas HSCs present 
in adult BM are mainly quiescent. In general, HSCs are at the top of the hema-
tological hierarchy and as other stem cells, they are capable of self-renewal, 
meaning the production of additional HSCs, as well as differentiation into all 
blood cell lineages (Orkin and Zon, 2008). 
A schematic overview of primitive and definitive hematopoiesis is shown in 




Figure 2: Simplified overview of primitive and definitive hematopoiesis. (adapted from 
(Jagannathan-Bogdan and Zon, 2013)) 
 
3.3.2 The caudal-related homeobox transcription factor family member 2 
(CDX2)  
3.3.2.1 The Cdx2-Hox axis in embryonic and adult hematopoiesis 
The Cdx genes, homologues of the Drosophila caudal gene, are a highly con-
served family of DNA-binding homeobox transcription factors classically 
known as regulators of axial elongation and anterior-posterior patterning 
during early embryogenesis (Chawengsaksophak et al., 2004). In mice and 
humans, the Cdx family consists of three members (Cdx1, Cdx2 and Cdx4). 
The first link between cdx genes and developmental hematopoiesis was made 
in zebrafish. In this model, the kugelig (kgg) mutant displaying defective 
erythropoiesis was identified as mutated in cdx4 (Davidson et al., 2003). cdx 
genes were then demonstrated to redundantly regulate embryonic hemato-
poiesis via activation of downstream hox genes (Davidson et al., 2003; 
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Davidson and Zon, 2006). Furthermore, a conserved Cdx-Hox pathway was 
documented to pattern hemogenic mesoderm and blood cells from in vitro 
differentiating murine embryonic stem cells (ESCs) and human pluripotent 
stem cells (Lengerke et al., 2009; Lengerke et al., 2007; Lengerke et al., 2008; 
McKinney-Freeman et al., 2008).  
Of note, only very mild decreases in clonogenic capacity were observed in in 
vitro CFU assays performed with differentiating Cdx1-/- and Cdx4-/- murine 
ESCs (Wang et al., 2008). Consistently, Cdx4 knockout mice, as well as Cdx1 
knockout mice show no major defects in hematopoiesis (Jedrusik et al., 2008; 
Koo et al., 2010; Subramanian et al., 1995), indicating that alone, Cdx4 and 
Cdx1 are dispensable for normal adult HSC functions in mice, possibly be-
cause they are compensated by other Cdx genes.  
In contrast to this, Cdx2-/- ESCs show more profound defects leading to per-
turbed expression of Hox genes and other genes involved in signal transduc-
tion, cell growth, proliferation and hematopoiesis (Wang et al., 2008). Cdx2-/- 
mice are embryonic lethal due to its essential roles in the trophoblast of the 
pre-implantation embryo (Chawengsaksophak et al., 1997). Studies using 
conditional Cre-mediated knockouts of Cdx1 and Cdx2 at the same time 
showed that these double mutants display major defects in primitive hemato-
poiesis as well as yolk sac vasculature (Brooke-Bisschop et al., 2017). 
In the adult hematopoietic system, Hox genes are preferentially expressed in 
immature healthy stem/progenitors and in malignant hematopoietic cells. 
Hoxa9-/- BM cells manifest a severe defect on the level of HSCs and committed 
progenitors, and constitutive expression of Hoxb4 increases self-renewal ca-
pacity of murine HSCs without initiating leukemic transformation. In contrast 
to this, aberrant expression of e.g. Hoxa9 or Hoxa10 was reported to induce 
myeloid leukemia in murine experimental models (Rawat et al., 2012). 
 
3.3.2.2 CDX genes and their role in leukemia 
In the human adult, CDX2 expression is mainly detectable in epithelial cells of 
the gastro-intestinal tract, where it regulates proliferation and differentiation 
(James et al., 1994). In the colon, CDX2 was involved as tumor suppressor 
whereas in the stomach and esophagus ectopic CDX2 expression was linked 
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to the development of precancerous intestinal metaplasia (Almeida et al., 
2003; Eda et al., 2003). 
In 2004, Rawat and co-workers detected ectopic CDX2 expression in 
t(12;13)(p13;q12) AML, and involved CDX2 as fusion partner for the ETV6 
gene in this AML subtype. In a murine model, they then experimentally 
showed that Cdx2 overexpression induces myeloid leukemia, as shown in 
mice transplanted with Cdx2 overexpressing BM cells which then rapidly de-
veloped fatal and transplantable AML. In contrast, co-expression of ETV6-
CDX2 and Cdx2 in BM cells showed no accelerated AML induction in trans-
planted mice when compared to Cdx2 alone (Rawat et al., 2004). 
Further investigations concerning the involvement of Cdx genes in leukemo-
genesis revealed CDX2 expression in 90% of patients with AML, while no 
CDX2 expression was detected in HSPCs derived from healthy individuals. In 
order to characterize the functional role of CDX2 in human AML, Scholl and 
colleagues generated a knockdown model of CDX2 (using shRNA) in several 
human AML cell lines. These experiments revealed growth inhibition and re-
duced clonogenicity in CDX2 knockdown AML cell lines. Furthermore, Cdx2 
overexpression in primary murine BM resulted in an increased serial CFU 
formation and replating activity. Together these data suggest that activated 
CDX2 expression is a frequent event in the pathogenesis of AML promoting 
proliferation and clonogenicity (Scholl et al., 2007). Previously, CDX2 was 
shown to act as positive upstream regulator of several HOX genes, which 
were linked to leukemogenesis in humans and mice, and deregulated HOX 
gene expression characterizes more than every third case of AML. The aber-
rant expression of HOXA9 and HOXA10 is for example strongly associated 
with certain AML subtypes (Debernardi et al., 2003; Rawat et al., 2008). Thus, 
several studies examined the crosstalk between CDX2 expression and expres-
sion of HOX genes. It was shown that constitutive expression of Cdx2 dysreg-
ulates the expression of several leukemogenic Hox genes including Hoxa10, 
Hoxb8, Hoxa6 and Hoxb6 (Rawat et al., 2008; Scholl et al., 2007). These findings 
suggest that CDX2 expression contributes to the altered HOX gene expression 
observed in many AML, and functionally link the leukemogenic potential of 
Cdx2 to its ability to dysregulate Hox genes. Consistently, expression levels of 
CDX2 and HOX genes were shown to closely correlate in a cohort of 115 pa-
tients with AML. Further confirming this notion, loss of the ability of Cdx2 to 
perturb Hox gene expression – achieved by deletion of its N-terminal transac-
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tivation domain – correlated with the inability of Cdx2 to induce AML in mice 
(Rawat et al., 2008).  
Notably, aberrant expression of CDX2 was furthermore reported in ca. 80% of 
cases with B- or T-lineage acute lymphoblastic leukemia (ALL) in adult as 
well as pediatric patients, where high CDX2 gene expression levels associated 
with poor treatment outcome and inferior overall survival (Thoene et al., 
2009) (Riedt et al., 2009). Compatible with these findings, functional analyses 
showed that overexpression of Cdx2 in murine BM progenitors perturbed 
genes involved in lymphoid development (Thoene et al., 2009). CDX2 expres-
sion has also been found in subgroups of patients with myelodysplasia and 
chronic myelogenous leukemia (CML). Further analyses showed that in a low 
number of these patients, enhanced CDX2 expression was associated with 
transit into secondary AML as well as blast and accelerated phase, respective-
ly (Scholl et al., 2007). In contrast to data published in AML, CDX2 expression 
was not found to correlate with deregulation of specific HOX genes in pediat-
ric ALL (Lengerke and Daley, 2012). Another study reported CDX2 expres-
sion in 61% of patients with de novo adult ALL and decrease of CDX2 expres-
sion with complete remission and increase in relapse (Rawat et al., 2012).  
Molecularly, suppression of the transcription factor KLF4 was reported to be 
an important feature of the leukemogenic activity of CDX2 in AML. Further-
more, deregulation of the PPARγ signaling pathway was identified as in-
volved in CDX2-induced AML. Experiments using a PPARγ agonist revealed 
de-repression of KLF4 expression to result in toxicity of CDX2 positive leuke-
mic cells (Faber et al., 2013). 
Cdx4 was also shown to activate Hox genes and to induce AML in murine 
models, although with much longer latency. In these experiments, however, 
leukemia occurred in median after 300 days, suggesting that Cdx4 by itself is 
insufficient to drive leukemogenesis and secondary genetic events (which 
remain yet uncharacterized) needed to be aquired (Bansal et al., 2006). As 
such, co-expression of Cdx4 with Meis1a, a known Hox co-factor, was indeed 
able to accelerate leukemia induction in mice (Frohling et al., 2007).  
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3.3.2.3 The link between WNT signaling and CDX genes 
Experiments using murine ESCs for the characterization of hematopoietic fate 
by activation of the Cdx-Hox pathway showed a link between LEF1, a Wnt ef-
fector molecule and bone morphogenic protein 4 (BMP4) as up-stream activa-
tors of the Cdx-Hox pathway. More clearly, when BMP signaling was blocked 
in these studies, this resulted in suppressed Cdx1 and Cdx4 expression and 
hematopoietic development. However, ectopic activation of CDX or HOX 
genes was able to restore hematopoietic development in the absence of up-
stream BMP and WNT signaling. These findings indicate that BMP4 and WNT 
signaling are upstream of the Cdx-Hox pathway during hematopoietic devel-
opment. Consistently, direct activation of the Cdx1 promoter was reported for 
the Wnt effector LEF1 (Lengerke et al., 2008). Interestingly, van de Ven et al. 
later showed that in Cdx mutants, Cdx expression can be restored and pheno-
typic posterior defects corrected by posterior gain of function of Lef1 (van de 
Ven et al., 2011), suggesting that Wnt signaling also acts downstream of Cdx 
proteins. In accordance to this, overexpression of Cdx1 and Cdx4 in murine 
ESCs was shown to induce Wnt3a (Lengerke et al., 2008). Furthermore, 
zebrafish cdx4 expression was shown to be influenced by Wnt levels, however 
the precise underlying molecular mechanisms are not yet fully elucidated. In 
2011, Ro and Dawid suggested that tcf3 suppresses cdx4 expression through 
direct binding to multiple sites in the cdx4 gene regulatory region (Ro and 
Dawid, 2011). Sherwood and colleagues investigated the role of Wnt signaling 
in intestinal specification and regionalization. They showed that either genetic 
or chemical Wnt pathway activation leads to induction of Cdx2 as an intestinal 
master regulator acting directly on the endoderm, which induces gene ex-
pression specific for an intestinal program (Sherwood et al., 2011). In regard 
to neurogenesis, decrease in Cdx expression in mouse Cdx mutants leads to 
progressively more severe posterior vertebral defects, but these defects could 
be rescued by posterior Lef1 gain of function, indicating that Wnt signaling 
acts downstream of Cdx genes. The observations made by Cesca van de Ven 
concerning phenotype and transcriptome analysis in early Cdx mutants, ge-
netic rescue experiments and gene expression analyses indicated that the Cdx 
family of transcription factors acts via Wnt signaling during formation of the 
uro-rectal mesoderm (van de Ven et al., 2011). Beyond this, in the context of 
neural crest development, which involves induction of Pax3 expression by 
posteriorizing Wnt / β-Catenin signaling, several reports suggest a role for Cdx 
transcription factors in this process acting as intermediates between Wnt-
mediated regulation of murine Pax3 expression. For these experiments, 
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Sanchez-Ferras used embryonic carcinoma cells cultured in the presence or 
absence of Wnt3a-conditioned medium, which is known for activating the ca-
nonical Wnt-pathway (Sanchez-Ferras et al., 2012). Treatment with Wnt3a-
conditioned medium resulted in rapid induction of the expression of each Cdx 
member within 2 - 4 hours. In contrast to this, Pax3 induction was observed 
considerably delayed (after 18 hours) suggesting an indirect regulation by 
Cdx genes. For further characterization, experiments using the protein synthe-
sis inhibitor CHX were performed for analysis of direct interactions between 
Wnt signaling and Cdx genes. Cdx4 and Cdx1 are known to be direct targets of 
the canonical Wnt pathway (Pilon et al., 2006; Pilon et al., 2007) and therefore 
Cdx1 and Cdx4 induction by Wnt3a-conditioned medium was not affected by 
inhibition of de novo protein synthesis. Interestingly, Cdx2 induction was also 
found to be independent of de novo protein synthesis suggesting Cdx2 as a di-
rect target of Wnt / β-Catenin signaling in this model (Sanchez-Ferras et al., 
2012).  
In colon cancer, evidence for a functional crosstalk between Wnt and Cdx was 
found, since Cdx2 was determined to cooperate with Wnt signaling to regu-
late Claudin-1 expression in this tumor entity. Dysregulation of tight junctions 
is often associated with carcinogenesis and recent studies also support the 
role of tight junction integral proteins, such as Claudin-1, in the regulation of 
epithelial-to-mesenchymal transition (EMT). Claudin-1 expression is highly 
increased in colon cancer and is associated with tumor growth and progres-
sion. In this context, Bhat and colleagues showed key roles of Cdx1, Cdx2 and 
Gata4 in the regulation of claudin-1 expression, with Cdx2 overexpression re-
sulting in strongest claudin-1 mRNA induction. Co-expression of activated β-
Catenin further induced in a Cdx2-dependent manner up-regulation of Clau-













During the last decades the need for personalized targeted therapy in AML 
treatment became more evident due to further characterization of the disease 
regarding molecular and cytogenetic variants making their heterogeneity 
even more obvious. In particular, the characterization and identification of the 
so-called leukemic stem cells is highly important. These cells are responsible 
for leukemia initiation, maintenance and further relapse, and therefore have 
to be eradicated for making a cure possible.   
The projects presented in this PhD thesis build up on these features and aim 
to optimize the xenotransplantation model of human AML cells into NSG 
mice for its further usage to study mechanistic aspects of leukemia initiation.  
The obtained results promise (1) to improve xenotransplantation efficacy and 
enlarge the use of this model, and (2) to identify key mechanisms regulating 
the interaction of AML cells with their environment and thus in vivo leuke-










5.1 Improvement of the xenotransplantation model of human AML 
5.1.1 Long-term observation reveals high-frequency engraftment of hu-
man acute myeloid leukemia in immunodeficient mice  
Since primary human AML cells are notoriously hard to culture in vitro and 
rely on complex interactions with the microenvironment, in vivo mouse mod-
els are mandatory to further study the disease. Long-term AML in vitro cul-
tures are cumbersome and, besides one individual report performing such 
cultures (Sontakke et al., 2014), a robust protocol that can be reproducibly 
used by different research groups and across AML subtypes is still missing. 
Murine leukemia models are well established and have several advantages 
such as well-characterized disease and high reproducibility with respect to 
disease kinetics. Importantly, since these models are mostly generated by a 
limited number of genetic events, they cannot fully depict the human disease 
heterogeneity. Xenotransplantation assays into immunosuppressed mice in-
stead enable studies with primary human cells that accommodate a wider 
range of genetic heterogeneity. 
The first successful engraftment of primary human AML cells in mice was re-
ported in SCID mice already in 1994 (Lapidot et al., 1994). Over the past dec-
ades, many efforts in optimizing the xenotransplantation model have been 
made by improving the congenic murine environment for the transplanted 
cells (e.g. higher immunosuppression (NSG mice), genetic knock-ins of hu-
man cytokines (“humanized mice” (Theocharides et al., 2016)) or impairment 
of the endogenous HSCs (kit mutation (Cosgun et al., 2014))). Nevertheless, 
most previously published data reported that a wide percentage of human 
AML (~34-60%) fail to engraft mice (Eppert et al., 2011; Sanchez et al., 2009), 
and thus cannot be studied in vivo. These studies however have pursued a 
limited follow-up of 12 to maximum 16 weeks post-transplantation, which are 
time-frames typically used to investigate the engraftment of healthy HSCs 
(Mazurier et al., 2003; Notta et al., 2010). In these reports, mice were analyzed 
at these time-points in BM and peripheral blood (PB) and if less than 1% (or 
respectively 0.1%) of human among murine cells were detected across all 
transplanted mice, the corresponding AML was scored as non-engraftable 
(Eppert et al., 2011; Lapidot et al., 1994; Sanchez et al., 2009). Interestingly, us-
ing this method, almost only AML samples belonging to aggressive molecular 
subtypes (intermediate and poor risk AML according to the ELN classifica-
tion, often showing FLT3-ITD mutations) but not favorable risk AML cases 
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were shown to engraft (Eppert et al., 2011; Rombouts et al., 2000a; Rombouts 
et al., 2000b; Sanchez et al., 2009), leaving latter largely understudied in vivo.  
In our study (Paczulla et al., 2017), we hypothesized that favorable risk AML 
can also successfully engraft mice, if longer observation time is provided. We 
transplanted leukemic cells derived from PBMCs of a mixed cohort of prima-
ry AML (n=19, among which n=4 favorable risk AML). Cells were transplant-
ed intravenously via the tail vein or intrafemorally in preferentially sub-
lethally irradiated but also in non-irradiated NSG mice. Animals were moni-
tored for signs of disease and human engraftment via flow cytometry of BM 
biopsies taken routinely every four weeks in one mouse per each experi-
mental group. Experiments were terminated at sickness or detection of >1% 
human AML among murine cells (Bonnet and Dick, 1997; Eppert et al., 2011; 
Lapidot et al., 1994).  
Indeed, our data indicate that extending post-transplant follow-up to 1 year 
per se allows robust engraftment and symptomatic leukemia induction from 
nearly every transplanted AML sample (18/19, ~95%), including also favora-
ble risk subtypes (e.g. inv(16), previously considered mostly non-engraftable 
in NSG mice). To investigate engraftment at standardized time-points used in 
previous studies, we additionally screened all transplanted mice for infiltra-
tion with human AML cells in the BM by performing BM puncture on anaes-
thetised animals. At 16 weeks post-transplantation, indeed only 7 out of 19 
AML samples (~37%, termed standard engrafters) showed engraftment, con-
firming observations from previous studies reports (Eppert et al., 2011). How-
ever, several mice scored as non-engraftable at this time-point did develop 
leukemia after longer latency, as shown by analyses performed on the same 
animals at later time-points. As such, the median time to engraftment in our 
study was 22 ± 9 weeks; in the majority of cases (11 out of 19 AML, ~58%, 
termed long-latency engrafters) leukemic repopulation would have been 
missed using published protocols (Figure 3A and 3B). The fact that BM biop-
sies taken at 16 weeks failed to detect leukemic cells in these long latency en-
grafters (11/18, 61%), indicates that leukemic cells can persist in vivo over 




Engraftment was confirmed by multi-parameter flow cytometry, histopathol-
ogy and next generation sequencing (NGS) showing conserved immune phe-
notypes and clonal architecture in mouse-derived leukemic cells. Interesting-
ly, time to engraftment and mouse survival were influenced by the AML mo-
lecular risk group (Figure 3C) but not by in vitro colony forming capacity or 
percentage of CD34+(CD38-) cells which both also did not correlate with in vi-
vo leukemia kinetics (Paczulla et al., 2017). One possible explanation for the 
longer time to in vivo leukemia induction in some AML is, as we found, their 
lower content in LSC and LSC-like cells that can home to the BM (Figure 3D). 
 
In summary, we have developed a model that allows in vivo leukemogenesis 
studies in the vast majority of AML (including favorable risk disease subtypes 
previously considered non-engraftable). In the following, this model will be 
used to investigate the effects of genetic or pharmacologic interventions on in 





Figure 3: Extended post-transplant follow-up enhances engraftment efficiency of human 
AML in NSG mice and shows that in vivo leukemogenesis correlates with molecular risk 
group stratification and differences in homing rates. (A) Quantification of engrafted sam-
ples at 8-10 weeks, 12-14 weeks and 16 weeks versus one year. A Fisher’s exact test was used 
to calculate statistical significance between engrafters and non-engrafters at each analyzed 
time period to our endpoint of 1-year observation time. (B) Kaplan-Meier survival analysis of 
n=109 mice after xenotransplantation with human primary AML cells showing that ~95% of 
mice die from leukemia after 1 year of observation time. (C) Kaplan-Meier survival analysis 
of n=99 mice (n=10 mice were transplanted with APL and are therefore not included in this 
statistic) show that mice transplanted with favorable risk AML showed longest survival 
when compared to intermediate and respectively adverse risk cases (black: favorable, n=4; 
blue: intermediate, n=8; red: adverse risk AML, n=3). (D) The homing rate of leukemic cells in 
the BM was higher in standard compared to long-latency engrafters. Data from n=3 AML pa-
tients with n=3-5 mice each are shown for each group. (Paczulla et al., 2017) 
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5.1.2 Investigation of catecholamine-based mechanisms regulating leu-
kemia induction in a xenotransplantation model of human AML 
5.1.2.1 Xenotransplantation at night accelerates leukemogenesis  
Using the model described above in 5.1.1, we observed that xenotransplanta-
tions performed at night (respectively very early in the morning, at 3 am) ac-
celerated engraftment when compared to transplantations performed in the 
late afternoon (5 pm) (see the experimental time schedule in Figure 4). There-
fore, we analyzed this parameter as a method to optimize our AML xeno-
transplantation model and aimed to investigate the underlying mechanisms, 
which according to our results so far involve enhanced catecholamine activity 
in mice transplanted at 3 am.  
 
                      
Figure 4. Time schedule of day and night transplantations. Please note that during night, 
mice were exposed to light one hour prior to and after transplantation. ZT = Zeitgeber time 
with ZT0 = time-point of light onset and ZT12 = time-point of light offset. 
 
We first transplanted primary AML blasts side-by-side at the two time-points 
(“night”: 3 am and “day”: 5 pm) and used the same patient cells for day and 
night transplantations. Of note, cells were thawed separately and treated 
equally for the day and the corresponding night experiment. Transplantation 
at night resulted in higher engraftment when compared to transplantation at 
daytime (shown for n=5 AML cases transplanted at both time-points, Figure 
5A). These findings were further confirmed by histopathology showing mi-
cro-leukemic infiltrations in the BM of mice transplanted during day while 
mice transplanted during night showed very high leukemic infiltration (Fig-
ure 5B). When limiting dilution experiments were performed, the results from 
the long-term assays could be reproduced and even improved, since most of 
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the mice transplanted during day with the lowest cell dosage did not develop 
leukemia up to one year after transplantation. In contrast to this, all mice 
transplanted during night resulted in leukemic engraftment (Figure 5C). 
To further investigate the mechanisms underlying this phenomenon, we per-
formed homing assays with CFSE labeled AML cells, since the main physio-
logical process happening directly after xenotransplantation is the migra-
tion/homing of the transplanted cells into BM. We therefore hypothesized that 
this process would be mostly influenced by the time-point of injection. These 
experiments showed that indeed, cells from the same AML sample show 
higher homing rates (not only to BM, but also to liver and spleen) upon xeno-
transplantation via the tail vein at night compared to day time (Figure 5D); in 
contrast, cells measured in the PB were reduced in mice transplanted at night. 
 
 






































































Figure 5. Transplantation (tx) at night facilitates long-term AML engraftment and enhances 
homing (in comparison to conventional day-time transplantation). (A) Shown are percent-
ages of engrafted human AML cells as detected by multi-parameter flow cytometry after 
staining with human antibodies in mice transplanted with cells from the same AML sample 
at day and respectively night following otherwise exactly similar procedures. Data from n=5 
independent experiments using different AML patient samples with n=4-5 mice per group 
and sample are shown. (B) Histopathological confirmation of leukemic infiltration in the BM. 
Shown are representative H&E as well as anti-human CD33 stainings. (C) Kaplan-Meier 
analysis of limiting dilution assays (using 5x105 and 1x105 cells/mouse) with n=2 patient sam-
ples and n=10 mice per arm in total. (D) Homing assays showing that night transplantation 
enhances homing to the BM but also to liver and spleen. Conversely, fewer cells are detecta-
ble in the PB. Shown are summarized data from seven independent experiments performed 
with different AML samples (33 mice per group in total); individual patient-specific analyses 
also showed the same result. A Mann-Whitney U Test (for not normally distributed data) or 
students t-test (for normally distributed data) was used for statistical analyses with n.s. = not 
significant (p > 0.05), * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
 
So far, the SDF1-CXCR4 axis was described as the main molecular regulator 
of HSC homing to the BM. The SDF1-CXCR4 axis was indeed shown to follow 
circadian oscillations. After light exposure, SDF1 is released as chemoattract-
ant from the BM while SDF1 mRNA is down-regulated; this leads to higher 
HSC mobilization and therefore enhanced levels of circulating HSCs, showing 
a peak at 5 hours after light onset (Méndez-Ferrer et al., 2008). It is possible 
that enhanced mobilization of endogenous HSCs into the circulation might 
open up niche space and then facilitate repopulation with transplanted AML 
cells. However, in our experimental setting, mice were exposed to light 1 hour 
prior to transplantation and 1 additional hour after transplantation (Figure 4). 
Thus, the time-point of transplantation is not corresponding to the peak of 
HSC mobilization. Consistently, we only detected slight changes in BM-SDF1 
(and no changes in PB-SDF-1), when our two transplantation time-points 
were compared. Furthermore, in vitro colony forming assays of PBMCs de-
rived from mice at these two experimental time-points (3 am, 5 pm) showed 
no significant difference, suggesting that the numbers of circulating HSPCs 
are comparable. These data overall indicate that alternative mechanisms (e.g. 
induction of adhesion molecules) are responsible for the engraftment ad-
vantage observed at night. In support of this hypothesis, we also observed 
that night transplantation enhanced AML cell homing to liver and spleen 
(Figure 5D).  
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5.1.2.2 Increased catecholamine levels mediate – in part – the “night effect” 
Notably, we observed that mice - which are naturally more active at night - 
showed more distress when they were disturbed by light exposure and trans-
plantation during night when compared to day time.  
In our fast society and everyday life stress becomes an important factor affect-
ing our health, since it broadly influences our body by e.g. deregulating cir-
cadian rhythms, blood pressure, the cardiac cycle up to panic attacks (Esler et 
al., 2008). Links between stress levels and cancer development were investi-
gated and some associations reported. In 2016, Weberpals and co-workers 
published a meta-analysis of 88.026 cancer patients from 30 different studies. 
They showed that patients receiving beta-blockers had a significantly higher 
overall and cancer-specific survival (Weberpals et al., 2016) indicating a role 
of beta-adrenergic signaling in cancer progression. Shortly after this study, a 
report in line with this notion was published, showing that activation of beta-
adrenergic signaling in several human tumor cells and entities results in 
higher invasiveness and cell deformability (shown in breast, ovarian, prostate 
and melanoma cancer cells as well as for leukemic cells) (Kim et al., 2016). 
Moreover the authors postulate a scheme of the putative mechanisms behind 
these observations suggesting that catecholamines induce beta-adrenergic 
signaling in cancer cells leading to an internal cascade starting from produc-
tion of cAMP, in the following activation of the PKA signaling, which in 
terms results in higher Ca2+ efflux from the endoplasmatic reticulum (ER), fi-
nally leading to an increase in cortical actin and cytoplasmic F-actin for leu-
kemic cells (Figure 6) (Kim et al., 2016). These cortical actin dynamics have 
furthermore been linked to cadherin adhesion (de Rooij, 2014) indicating cad-
herin induction as a possible downstream effector of catecholamine activation 
in this setting.  
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Figure 6: Scheme of putative mechanisms how β-adrenergic signaling activation may influ-
ence invasiveness of cancer cells (from (Kim et al., 2016)). 
 
Moreover, also a link between circadian oscillations, SDF1 expression and 
catecholamines, as known activators of beta-adrenergic signaling, has been 
reported. For example, stimulation of β2-adrenergic receptors (ARs) in osteo-
blasts was shown to induce clock gene expression, whereas β3-AR activation 
results in acute SDF1 mRNA down-regulation, which are compensatory 
mechanisms involved in the above-mentioned circadian mobilization of HSCs 
(Fu et al., 2005; Liu et al., 2007; Méndez-Ferrer et al., 2008). Until now, no 
functional relevance of circadian oscillations and catecholamines influencing 
leukemogenesis were shown in vivo. Therefore, we were wondering if the ob-
served increase in homing and leukemia initiation was mediated by higher 
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catecholamine (epinephrine and/or nor-epinephrine) levels affecting the BM 
niche, healthy murine HSCs and/or the transplanted human AML cells.  
To further explore this hypothesis, we measured epinephrine and nor-
epinephrine levels in the plasma and crushed femurs of mice at day and night 
(n=3 each group) by using ELISAs as previously described (Heidt et al., 2014). 
These experiments showed especially enhanced epinephrine levels in mice 
analyzed at night (and after light exposure) compared to daytime in both, 
plasma and femur extracts (Figure 7A). We therefore performed additional in 
vivo assays during daytime by pre-treatment of mice with either epinephrine 
or carrier control (PBS) and subsequent intravenous AML cell injection for 
long-term (Figure 7B) or Homing (Figure 7C) assays. We observed that indeed 
epinephrine injection accelerated long-term engraftment (Figure 7B) and re-
sulted in increased homing rates (Figure 7C). This was in part counter-acted 
by pre-treatment of mice with the beta-blocker propranolol (Figure 7C) with 
respect to both long-term leukemia induction (Figure 7D) and homing (Figure 


































































































































Figure 7. Epinephrine levels influence homing to the BM and long-term engraftment. (A) 
Epinephrine levels are higher in the plasma, when cells are transplanted at night versus day-
time (n=5 mice per group) as measured by ELISA. (B) Mice were treated with PBS or epi-
nephrine one hour before intravenous AML cell transplantation at daytime for long-term leu-
kemia induction leading to accelerated leukemia development. Shown are data from n=1 pa-
tient sample with n=4 mice per group. (C) Mice were treated with PBS, propranolol, epineph-
rine and a combination of both one hour prior to transplantation at daytime. Note that epi-
nephrine treatment increased homing to the BM, while this effect can be blocked by simulta-
neous administration of propranolol. Shown are summarized data from three different pa-
tient samples with n=3 mice per group. (D-E) Mice were treated with the β1/2-AR blocker 
propranolol one hour prior to transplantation at night after which (D) long-term leukemia 
induction and (E) homing were analyzed. Indeed, long-term leukemia engraftment was re-
duced in mice that were treated with propranolol one hour before cells were transplanted at 
night. Shown are summarized data from n=3 independent experiments with n=4-5 mice per 
group (D). Also homing properties were lower at daytime when compared to night trans-
plantations without prior propranolol treatment. Shown are summarized data from three dif-
ferent AML samples, transplanted during day and night (+/- propranolol) with n=3 
mice/patient and condition (E). A Mann-Whitney U Test (for not normally distributed data) 
or students t-test (for normally distributed data) was used for statistical analyses with n.s. = 
not significant (p > 0.05), * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
 
In conclusion, this project part shows that xenotransplantation at night into 
NSG mice can accelerate engraftment of human AML cells, thereby further 
optimizing this model. This possibly results from modulation of cell adhesion, 
which was enhanced upon addition of epinephrine to in vitro cultures of AML 
cells on stroma (Figure 8). This is in line with published data showing that 
catecholamines increase the invasiveness and cortical actin in cancer cells 




             
Figure 8. Epinephrine in adhesion assays increases adhesion of human AML cells. Adhe-
sion assays with different CFSE®-labeled cells were performed on MS-5 stroma cells with the 
addition of 10 µM epinephrine and quantified after 90 min using flow cytometry analyses for 
fluorescently labeled cells. Shown are data from (A) SKM-1 and EOL-1 cell lines and (B) pri-
mary human AML cells (n=3 patient samples). For experimental setup see also below sche-
matic overview of the procedure in Figure 12B. Data from n=3 independent experiments per-
formed in technical triplicates are shown. A students t-test was used for statistical analyses 
with * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
 
Taken together, with our study we could show for the first time a functional 
interaction of catecholamines, AML cells and the niche. Our data suggest that 
disturbing circadian rhythm might have pro-oncogenic effects, and that these 
are mediated by catecholamines and, importantly, can be partly prevented by 
beta-blocker treatment. These findings might be of general significance for 
tumor initiation processes, but however further investigations are required. 
Finally, if the role of catecholamines and associated adhesion molecules (most 
likely cadherins) is however conserved in healthy HSPCs, this knowledge 
might be used to improve their homing and engraftment in clinically em-
ployed stem cell transplantations in patients after induction therapy. Facilitat-
ing engraftment after stem cell transplantation promises to shorten the period 
until recovery of the blood system is achieved, and potentially allows trans-
plantation with lower cell doses, which might make it easier to find matching 
donors by enabling transplantation of individual cord blood samples (which 
currently cannot be used for adult transplantation because they contain low 
HSPC numbers). Overall this knowledge might have an important beneficiary 




































































































Follow-up work outside of the scope of the current thesis is planned and will 
further elucidate the mechanisms underlying enhanced homing and engraft-
ment of leukemic (and perhaps also of healthy HSPCs) observed after trans-
plantation at night-time and respectively in the presence of stimulated cate-
cholamine activity. 
 
5.2 Leukemia stem cells – Absence of NKG2D ligands defines hu-
man leukaemia stem cells and mediates their immune evasion 
(see also manuscript attached: Paczulla*, Rothfelder*, Raffel* et al., in revi-
sion in Nature) 
AML is considered to emerge from subpopulations of LSCs (Lapidot et al., 
1994). These cells in parts resemble HSCs, meaning that they can self-renew 
and show some degree of differentiation into more mature blasts (that them-
selves cannot initiate leukemia). Next to this, LSCs also show disease initiat-
ing properties, enhanced resistance to conventional chemotherapies and are 
thus thought to be responsible for relapse (Hanahan and Weinberg, 2000). 
Here we proposed that LSCs also selectively escape immune surveillance, 
when compared to more differentiated leukemic cells. The study of interac-
tions between human LSCs and the immune system have been hampered by 
the fact that immunosuppressed animals are used for xenotransplantation as-
says (as reviewed by Theocharides et al., 2016); thus, possible differences in 
response of LSCs and non-LSCs to immune cells remain elusive.  
LSCs were reported to preferentially reside among CD34+CD38- leukemic 
subpopulations (Bonnet and Dick, 1997; Lapidot et al., 1994), but were also 
identified among CD34- cells in CD34 non-expressing AML (Taussig et al., 
2010). Further markers have been reported to enrich LSCs in CD34 expressing 
AML (mostly within the previously described CD34+CD38- subpopulation), 
among these GPR56 (Daria et al., 2016; Pabst et al., 2016; Saito et al., 2013), 
CD123 (IL-3 receptor alpha chain) (Jin et al., 2009), CD25 (IL-2 receptor alpha-
chain) (Saito et al., 2010), CD96 (Hosen et al., 2007), CD47 (Majeti et al., 2009), 
CLL-1 (van Rhenen et al., 2007), CD44 (Jin et al., 2006), CD99 (Chung et al., 
2017) or TIM3 (Jan et al., 2011). Of note, AML cases show high heterogeneity 
regarding these markers and do not routinely express all of them in one sam-
ple hampering their routine use for LSC identification.   
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Surface expression of NKG2D ligands (NKG2DL) represents an activating 
signal for recognition and lysis through NKG2D receptor expressing NK cells. 
NKG2DL are not expressed on healthy cells but induced upon cellular stress, 
for example in response to infection or malignant transformation. In this pro-
ject, we demonstrate that LSCs selectively evade NKG2D-mediated immuno-
surveillance and clearance by suppressing NKG2DL. NKG2DL comprise dif-
ferent molecules of the MIC and ULBP protein families (Guerra et al., 2008). 
In cooperation with the Immunology & NK cells laboratory led by Professor 
Helmut Salih at the University of Tuebingen, Germany, we found that 
NKG2DL are heterogeneously expressed on AML cells in a cohort of 175 
AML patients as analyzed by flow cytometry (Figure 9A).  
Analyses of sorted NKG2DLpos and NKG2DLneg subpopulations of the same 
patients revealed that NKG2DLneg cells display stemness characteristics such 
as immature morphology (Figure 9B), stemness-associated gene expression 
signatures (Eppert et al., 2011; Ng et al., 2016) and enhanced in vitro clonogen-
icity (Figure 9C). Upon transplantation into NSG mice, we observed leukemia 
initiation only from NKG2DLneg cells (Figure 9D) that in vivo however were 
able to differentiate into NKG2DLpos cells, reconstituting the heterogeneous 
NKG2DL distribution observed in the pre-transplant sample. However, no 
leukemia induction was observed from corresponding NKG2DLpos cells (Fig-
ure 9D). In vivo chemoresistance assays using cytarabine injections at the stage 
of disease showed that NKG2DLneg cells significantly better survive the treat-
ment, which preferentially diminishes NKG2DLpos subpopulations. Moreover, 
co-culture experiments of bulk AML cells with polyclonal NK cells (pNKCs) 
enriched for AML cells with functional LSC properties as shown by higher 
colony-forming capacity and increased in vivo leukemogenesis, which could 
be blocked by addition of specific NKG2D blocking fragments during the co-
culture. 
These data show that LSCs are selectively protected from NK cell mediated 
lysis. Dulphy et al. recently summarized the current knowledge on the role of 
NK cells in AML (Dulphy et al., 2016). The fact that AML blasts are sensitive 
to NK cell-mediated immune response in vivo is also highlighted by studies in 
patients receiving an allogeneic HSC transplantation, in particular when us-
ing haplo-identical donors, who showed lower incidence of AML relapse if 
transplanted with stem cell concentrates containing allo-reactive NK cell 
clones against recipient cells (Ruggeri et al., 2002). By contrast, in patients 
who do not receive transplantation, NK cells are not activated via these 
 44 
mechanisms. Actually, autologous NK cells of patients with overt AML dis-
play severe defects (e.g. reduced expression of activating NK receptors, cyto-
toxicity and IFN-γ release), which are induced by AML cells via production of 
soluble immunosuppressive molecules, modification of the microenviron-
ment and direct cell-cell interactions leading to defective immunological syn-
apses (Dulphy et al., 2016). Interestingly however, NK cells appear to normal-
ize their function after induction of morphologic remission through chemo-
therapy (Fauriat et al., 2007; Khaznadar et al., 2015). Taken together, these da-
ta reinforce that AML cells actively hamper NK cell function at stages of overt 
disease, but also suggest that additional mechanisms are responsible for AML 
cell escape from NK immune surveillance at the stages of minimal residual 
disease, when leukemia initiation and relapse happen, making our new in-
sights highly important. 
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Figure 9. Absence of immunostimulatory NKG2DL enriches for LSCs. (A) upper panel: 
Representative NKG2DL staining. Lower panel: FACS analysis using NKG2D-Fc chimera 
showed heterogeneous percentages of NKG2DLneg (red) and NKG2DLpos (blue) AML cells 
within individual patients. (B-D) NKG2DLneg and NKG2DLpos subpopulations were sorted 
from a given AML patient and analyzed side-by-side at equal numbers. (B) Representative 
May-Grünwald-Giemsa staining (left) and corresponding flow cytometry scatter plots (right). 
(C) Colony formation (data from n=32 patients performed in technical triplicates each). (D) 
Transplantation of NKG2DLneg and corresponding NKG2DLpos AML fractions from the same 
AML patient sample in NSG mice: summarized results on human leukemic infiltration in 
mouse BM and PB as detected by flow cytometry (n=10 patient samples and n=3-5 mice per 
patient and group). A Mann-Whitney U Test (for not normally distributed data) or students t-
test (for normally distributed data) was used for statistical analyses with n.s. = not significant 
(p > 0.05), * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
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Around 30% of AML cases show no CD34 expression (termed CD34 non-
expressing AML) (Taussig et al., 2010). Although functional analyses indicate 
that the LSC concept holds true also in this subtype, a robust LSC marker has 
not yet been reported for this subgroup in which LSCs are thus understudied. 
In our study, we additionally analyzed 55 cases with CD34 non-expressing 
AML and also here observed heterogeneous distribution of NKG2DL among 
leukemic cells of individual patients (Figure 10A), with CD34-NKG2DLneg 
subpopulations being more clonogenic than their corresponding CD34-
NKG2DLpos counterparts (Figure 10B) and showing unique in vivo leukemia 
induction properties in NSG mice (Figure 10C). More detailed investigations 
on the relationship between CD34 and NKG2DL expression in CD34 express-
ing AMLs demonstrated that the CD34+ subpopulations displayed lower 
NKG2DL expression when compared to CD34- AML cells of the same patient 
(Figure 10D-E). Samples with >90% NKG2DLneg AML cells were enriched in 
CD34+CD38- compared to CD34+CD38+ and CD34- fractions (Figure 10F-G) 
confirming the inverse correlation between NKG2DL expression and stem-
ness. Consistent with the notion that not all CD34+ AML cells are LSCs, 
CD34+NKG2DLpos populations were also detected. This observation indicates 
that NKG2DL might be acquired during AML cell differentiation.  
These data provide molecular and functional evidence that absence of 
NKG2DL surface expression identifies LSCs in patients suffering from CD34 
expressing but also from CD34 non-expressing AML and demonstrate that 
absence of NKG2DL can be used as putative marker to enrich for LSCs in this 
AML subgroup. 













































































































































































Figure 10. Absence of NKG2DL identifies LSCs independently of CD34 expression. (A-C) 
CD34 non-expressing AML: (A) NKG2D-Fc flow cytometry analysis (left panel: representa-
tive plots; right panel: results from n=55 patients); (B-C) comparison of sorted NKG2DLneg 
versus corresponding NKG2DLpos AML cells showed (B) enhanced colony formation (data 
from n=10 patients in technical triplicates each) and (C) in vivo engraftment in NSG mice (data 
from n=5 patients in n=3-5 mice per patient and condition). (D-G) CD34 expressing AML: (D-
E) NKG2D-Fc flow cytometry analysis (left panel: representative plots; right panel: results 
from n=98 patients. (E) Shown is the summarized quantification of NKG2DL of 98 patients 
subdivided into CD34+ and CD34- populations. (F-G) NKG2D-Fc, anti-human CD34 and anti-
human CD38 co-staining: quantification of %NKG2DLneg cells among different AML subpop-
ulations, CD34+CD38-àCD34+CD38+àCD34- subsets, p<0.001; (F) quantification of samples 
with >90% NKG2DLneg cells per subpopulation among CD34+, CD34+CD38- and CD34- com-
partments. A Mann-Whitney U Test (for not normally distributed data) or students t-test (for 
normally distributed data) was used for statistical analyses with n.s. = not significant (p > 
0.05), * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
 
More detailed molecular analyses using RNAseq and gene expression arrays 
retrieved poly-ADP-ribose polymerase 1 (PARP1) as significantly up-
regulated gene in NKG2DLneg versus NKG2DLpos AML cells across several 
genetic subtypes (Figure 11A). Interestingly, treatment with PARP1 siRNA 
(Figure 11B) or alternatively with a PARP1 inhibitor (AG-14361, Figure 11C, 
left panel) was able to induce NKG2DL expression in CD34+ LSCs sensitizing 
these to NK cell mediated attack. Importantly treatment of cord blood derived 
CD34+ HSPCs did not result in NKG2DL induction (Figure 11C, right panel), 
suggesting that only leukemic but not healthy HSPCs are targeted by this 
treatment. Ultimately, in vivo co-treatment of mice transplanted with human 
AML cells with the PARP1 inhibitor AG-14361 and functional NK cells signif-
icantly reduced leukemia induction (2/16 leukemic/transplanted mice), while 
single treatments with AG-14361 or NK cells alone did not (Figure 11D-E). 
Importantly, pre-treatment of NK cells with a NKG2D-blocking agent abro-
gated these synergistic anti-leukemic effects, indicating NKG2D-dependence 
(Figure 11E). Together, these data indicate that enhanced PARP1 expression 
mediates NKG2D dependent immune escape in LSCs, thereby allowing these 
to grow out and initiate disease, at primary disease manifestation and at re-
lapse. 
These findings carry important translational significance since they indicate 
that LSCs selectively escape immune control and identify a way (PARP1 inhi-
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Figure 11. Increased PARP1 expression in LSCs contributes to their selective escape from 
NK cell immune surveillance. (A) Overlap of robustly differentially regulated genes in 
NKG2DLneg versus NKG2DLpos cells isolated from the same AMLs and analysed by gene ex-
pression arrays (n=5 AML in biological triplicates each) or RNA sequencing (n=5 AML). (B-C) 
Effects of in vitro PARP1 inhibition on NKG2DL expression. (B) Flow cytometry analysis for 
NKG2DL and anti-hCD34 after in vitro (24h) treatment of bulk AML cells with 3 different 
PARP1 siRNAs or scrambled control non-coding siRNAs (n=4 AMLs in technical triplicates 
each); left panel: exemplary flow cytometry plots, right panel: quantification of NKG2DLpos, 
and respectively CD34+NKG2DLposAML cells. (C) In vitro treatment with the PARP1 inhibitor 
AG-14361 (20µM) or DMSO carrier control. Left panel: exemplary flow cytometry plots and 
right panel: quantification of NKG2DL on CD34+ and CD34- subpopulations. Shown are data 
from treatment of AML cells (n=15 AML in technical triplicates each) and of healthy cord 
blood derived HSPCs (n=3 donors in technical triplicates each). Of note, induction of 
NKG2DL was only observed on AML cells but not on healthy HSPCs upon AG-14361 treat-
ment. (D-E) Leukemia development in NSG mice transplanted with AML cells and treated in 
vivo with AG-14361 or DMSO +/- pNKC (n=7-16 mice per condition. (D) Scheme of experi-
mental setup. (E) Summarized flow cytometry data of human leukemic engraftment in PB, 
BM and organs of mice. One dot represents one mouse. A Mann-Whitney U Test (for not 
normally distributed data) or students t-test (for normally distributed data) was used for sta-









5.3 Modeling the hematopoietic niche  
5.3.1 CDX2-driven non-cell autonomous effects in AML progression 
(manuscript in preparation: Paczulla et al). 
5.3.1.1 CDX2 expression regulates WNT signaling in leukemic cells  
CDX2 was previously reported to be expressed in a majority of human AML 
and ALL (see “3.3.2.2 CDX genes and their role in leukemia” in the Introduc-
tion Chapter 3) but not in healthy hematopoietic cells. CDX2 knockdown in 
human AML cells was shown to impair proliferation and clonogenicity in 
AML cell lines (Scholl et al., 2007).  These results were confirmed in additional 
AML cell lines (EOL-1 and SKM1) as well as primary AML patient samples, 
which upon lentiviral CDX2 knockdown all showed reduced clonogenic ca-
pacity in in vitro colony forming assays (Figure 12A), reduced in vitro adhe-
sion to stromal cells (Figure 12B-C), and reduced in vivo homing to the BM 
and leukemia initiation capacities upon transplantation in NSG mice (Figure 
12D-G). In contrast, no major effects were observed on growth, apoptosis, 
proliferation or cell cycle in these cells (data not shown). The majority of these 
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Figure 12. CDX2 knockdown in AML cells reduces their in vitro clonogenic and adhesive 
capacity as well as their in vivo leukemogenic potential. (A) Cells were plated in methyl-
cellulose and scored after 14 days showing decreased CFU formation in CDX2 knockdown 
cells. (B) Schematic overview of the adhesion assay and (C) quantification of fluorescently 
labeled adherent leukemic cells on stoma monolayer. In (A-C) summarized data from n=5 
independent experiments performed in technical triplicates are shown. (D-F) In vivo leukemia 
induction assay. NSG mice were transplanted with control or CDX2 knockdown EOL-1 and 
SKM-1 cells and monitored for engraftment. (D) Quantification of leukemic burden using 
multi-color flow cytometry after 3-4 weeks in mice transplanted with 5x104 AML cells (n=5 
mice per group and experiment); (E) Histopathological analyses of BM sections of transplant-
ed mice and (F) Kaplan-Meier survival analysis. (G) Homing assay using control and CDX2 
knockdown EOL-1 and SKM-1 cells. 1x106 cells/mouse were injected via the tail vein and mice 
were sacrificed after 16h and analyzed for leukemic cells in BM and PB by flow cytometry. A 
Mann-Whitney U Test (for not normally distributed data) or students t-test (for normally dis-
tributed data) was used for statistical analyses with n.s. = not significant (p > 0.05), * = p < 
0.05, ** = p < 0.01 and *** = p < 0.001. 
 
5.3.1.2 CDX2 regulates WNT signaling and DKK1 secretion in human AML 
cells 
On the molecular level, microarray and qRT-PCR gene expression analyses on 
CDX2 modified versus control AML cells confirmed cellular adhesion as one 
of the main pathways regulated in response to CDX2 modulation, consistent 
with our functional results reported above. Furthermore, in line with the pub-
lished role of CDX genes in regulation of WNT and HOX genes during devel-
opment (Davidson et al., 2003; Lengerke and Daley, 2012; McKinney-Freeman 
et al., 2008; Rawat et al., 2012), genes belonging to these categories were found 
to be modulated in response to CDX2 modification. Several studies have de-
scribed a crosstalk between Cdx genes and Wnt signaling, which was also re-
ported to be involved in leukemogenesis. Lengerke and colleagues for exam-
ple showed that Lef1, a Wnt effector molecule, mediates Bmp4 activation of 
Cdx genes (Lengerke et al., 2008), indicating that Wnt signaling acts upstream 
of Cdx genes. Surprisingly, van de Ven and co-workers showed that in Cdx 
mutants phenotypic defects can be corrected by posterior gain of function of 
Lef1. Consistently, overexpression of Cdx1 and Cdx4 in murine ESCs was 
shown to induce Wnt3a (Lengerke et al., 2008), suggesting that Wnt signaling 
also acts downstream of Cdx genes. Unexpectedly however, since in devel-
opment CDX genes are mostly reported as positive regulators of WNT signal-
ing, in our study CDX2 induction enhanced not only the expression of β-
Catenin but also the expression of the WNT-inhibitory molecule DKK-1, while 
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CDX2 suppression showed opposite effects for both genes. Flow cytometric 
analysis for activated β-Catenin confirmed lower levels in CDX2 knockdown 
compared to control cells and correspondingly enhanced levels in CDX2 
overexpressing cells. Furthermore, ELISAs revealed that the secretion of 
DKK1 protein was modulated in response to CDX2 expression. Therefore, we 
hypothesized that CDX2 positive AML cells may secrete DKK1 to modulate 
their interaction with the BM niche and thereby obtain competitive ad-
vantages over healthy HSPCs for niche occupation. It is known that the num-
ber of osteoblasts directly affects the number of long-term repopulating HSCs 
(Calvi et al., 2003; Zhang et al., 2003). Supporting our hypothesis, Fleming and 
co-workers (Fleming et al., 2008) showed that Wnt / β-Catenin signaling plays 
an essential role in maintaining HSCs in a quiescent state (Fleming et al., 
2008) by showing that constitutive overexpression of Dkk1 on murine osteo-
blasts leads to exhaustion of LT-HSCs (Fleming et al., 2008).  
Here we showed that supplementation of DKK-1 indeed reduced levels of ac-
tivated β-Catenin (Figure 13A), colony formation (Figure 13B) and adhesion 
to stroma (Figure 13C) in healthy cord blood derived HSPCs cultured in vitro, 
and, when administered in vivo (Figure 13D), decreased colony forming ca-
pacity in BM cells (Figure 13E). In contrast, DKK-1 supplementation did not 
alter levels of activated β-Catenin (Figure 13F), colony formation (Figure 13G) 
and adhesion to stroma (Figure 13H) in AML cells which themselves, alt-
hough they actively secrete DKK-1, are apparently less sensitive themselves 
to DKK-1 mediated WNT inhibition. This suggests CDX2 as a guard of WNT 
signaling in AML, which additionally, by DKK-1 secretion, confers leukemic 
cells competitive advantages over healthy HSPCs with respect to BM niche 
occupation (Figure 13I).  
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Figure 13. DKK-1 impairs HSPC but not AML function. (A-C) DKK-1 treatment (200 ng/ml) 
of cord blood (CB) derived CD34+ HSPCs in regard to (A) level of activated beta-Catenin, (B) 
colony formation and (C) adhesion capacity. (D-E) In vivo treatment of murine BM with hu-
man recombinant DKK-1 protein. (D) Schematic overview of the experimental set-up. In 
brief, mice were treated via intrafemoral injection with either PBS control or DKK-1 (n=3 mice 
per group) and after 5 days sacrificed and analyzed for colony forming capacity (E). Quantifi-
cation of scored CFU assays at day 14 performed in technical triplicates per femur and 
mouse. (F-H) DKK-1 treatment of AML cell lines (EOL-1 and SKM-1) and primary AML cells 
in regard to (F) level of activated beta-Catenin, (G) colony formation and (H) adhesion capac-
ity. (I) Suggested scheme of mechanisms indicating CDX2 as a guard of WNT signaling in 
AML cells using DKK-1 secretion to out-compete healthy HSPCs. A Mann-Whitney U Test 
(for not normally distributed data) or students t-test (for normally distributed data) was used 
for statistical analyses with n.s. = not significant (p > 0.05), * = p < 0.05, ** = p < 0.01 and *** = p 
< 0.001. 
 
5.3.1.3 Treatment with WNT activators protects healthy HSPCs from leuke-
mic cell derived CDX2-DKK1-mediated WNT inhibition  
Building up on these findings, we hypothesized that in contrast to the notion 
of WNT inhibition in AML treatment, activation of WNT signaling could 
strengthen the healthy HSPCs in order to gain a competitive and protective 
advantage against DKK-1 secretion of AML cells and their subsequent niche 
occupation. A report from 2005 showed that both bone formation and bone 
mass were increased upon treatment with the known WNT agonist lithium 
chloride (LiCl) in mice (Clément-Lacroix et al., 2005). Therefore we postulated 
that WNT activation might on the one hand protect the healthy HSPCs against 
secreted DKK-1 by AML cells and on the other hand might strengthen the 
bone and subsequently also the hematopoietic niche. For further investiga-
tions, we first treated both AML cells and healthy HSPCs in vitro with LiCl 
and the GSK3 inhibitor SB216763 and observed - as expected - increased acti-
vated β-Catenin levels in both AML cells and healthy HSPCs (Figure 14A+D). 
In contrast to the results obtained with DKK-1 supplementation (Figure 13), 
healthy HSPCs showed slightly improved colony formation (Figure 14B) and 
enhanced adhesion to stroma (Figure 14C). However upon this treatment, 
AML cells showed impaired clonogenicity (Figure 14E), decreased adhesion 
(Figure 14F) and in co-cultures disadvantages regarding competitive adhesion 
resembling the CDX2 knockdown phenotype. In order to analyze the func-
tional effect of WNT activation in vivo, NSG mice were transplanted with 
AML cells and treated with LiCl or the respective vehicle control (Figure 
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14G). Engraftment data indicate impaired leukemic infiltration in mice in 
which LiCl was administered in the water compared to control treated mice 
with AML cell lines and primary cells (Figure 14H). 
In summary, our data unravels a novel non-cell-autonomous role by which 
the transcriptional regulator CDX2 promotes leukemogenesis, namely via 
DKK1 secretion to modify the hematopoietic BM niche and outcompete resi-
dent healthy HSPCs. We propose that CDX2 positive leukemic cells use CDX2 
to sustain their own β-Catenin activity despite the expression and allow secre-
tion of DKK1, which in turn is used to disturb the WNT levels in surrounding 
CDX2 negative healthy HSPCs thereby inducing their differentiation and re-
lease from protective BM niches – that then can be seeded by AML cells. 
Treatment with WNT agonists counteracting the WNT inhibition induced by 
AML cells in healthy HSPCs and the niche might be a promising strategy to 
impair leukemogenesis, among others via the restoration of healthy competi-
tor cells and impairment of leukemic cells at the same time. Future studies are 




Figure 14. Treatment with the WNT agonist lithium chloride (LiCl) strengthens healthy 
HSPCs while impairing AML function. (A-C) In vitro LiCl treatment of cord blood derived 
CD34+ HSPCs in regard to (A) level of activated β-Catenin, (B) colony formation and (C) ad-
hesion capacity. (D-F) LiCl treatment of AML cell lines (EOL-1 and SKM-1) and primary 
AML cells in regard to (D) level of activated beta-Catenin, (E) colony formation and (F) adhe-
sion capacity. (G-H) In vivo treatment with LiCl. (G) Schematic overview of the experimental 
set-up. In brief, mice were transplanted via intravenous injection with primary AML samples 
(n=1 patient) and after one week treated with LiCl or control vehicle in drinking water until 
engraftment was detected. (H) Quantification of engrafted human leukemic cells in murine 
BM in control compared to LiCl mice (n=4 mice per group). A Mann-Whitney U Test (for not 
normally distributed data) or students t-test (for normally distributed data) was used for sta-

















































































































































































5.3.2 Biomimetic engineering of a functional ex vivo human hematopoi-
etic niche  
As indicated above, healthy hematopoiesis is dependent on close interactions 
with the BM niche. Many studies in the last years have focused on unraveling 
and characterizing the “home” of HSCs in the murine BM (Morrison and 
Scadden, 2014; Méndez-Ferrer et al., 2010). The hematopoietic niche is very 
complex and builds a network that enables the regulation of HSC self-renewal 
and differentiation by cellular (e.g. mesenchymal stem cells (MSCs) with es-
sential roles in maintaining tissue homeostasis in the HSC niche) (Kfoury and 
Scadden, 2015), molecular (e.g. by cytokines regulating HSC fate) (Rieger et 
al., 2009; Zhang and Lodish, 2008) and structural components (e.g. interac-
tions with the extracellular matrix) (Guilak et al., 2009) defining the HSC 
niche. However, the components and interactions of the human HSC niche 
are poorly understood due to human material accessibility and limits of exist-
ing in vitro culture models. The development of an in vitro human BM surro-
gate niche system would offer a tunable platform to study hematopoiesis, 
which may enable unique insights in the regulation of the healthy (and in fu-
ture also of the leukemic) BM niche. Conventional systems fail at both captur-
ing the complexity of the BM niche while allowing the maintenance of func-
tional HSCs. Previous studies have attempted to maintain human HSPCs in 
vitro by adding different substrates as cytokines or chemoattractants or in vivo 
in humanized mouse models in order to get specific mature blood cells 
(Rongvaux et al., 2014). However, the complex organization of the BM with 
all its structures and cellular interactions that are necessary for the functional 
maintenance of HSCs could not yet be recapitulated in vitro so far.  
The need for advanced culture systems of higher biological complexity has 
gained increasing recognition (Vunjak-Novakovic and Scadden, 2011) in or-
der to study the biology of stem cells. The in vitro engineering of human BM 
environments (Dellatore et al., 2008; Di Maggio et al., 2011; Peerani and 
Zandstra, 2010; Vunjak-Novakovic and Scadden, 2011) capable to sustain 
HSCs (Peerani and Zandstra, 2010) would enable their study in xeno-free set-
tings similarly to the “organogenesis in a dish” proposed for complex organs 
using human induced pluripotent stem cells (iPSCs) (e.g. lung (Wilkinson et 
al., 2017), kidney (Takasato et al., 2015) and liver (Takebe et al., 2013)).  
In this study, a human 3D (BM) analogue was established in a perfusion-
based bioreactor system, partially recapitulating structural, compositional 
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and organizational features of the native human osteoblastic niche environ-
ment. This approach uses porous hydroxyapatite scaffolds with structural 
and compositional features of bone as described previously (Porter et al., 
2009), functionalized by human MSCs and the extracellular matrix (ECM) 
components deposited during their progressive maturation into the osteo-
blastic lineage. The perfusion flow bioreactor system was used for human 
MSC cultures offering efficient nutrient supply and waste removal at the 
same time (Wendt et al., 2003), while mimicking interstitial flow and associat-
ed shear stress. The blood compartment was introduced into the resulting 3D 
stromal tissue by perfusion of human purified CB derived CD34+ cells result-
ing in an engineered organoid capable to mimic structural and functional fea-
tures of the human BM supporting the maintenance of HSC properties.  
This provides an advanced technological platform of broad fundamental and 
translational relevance, including the study of human HSC biology and inter-
actions with their niche, the expansion of functional human HSCs, or the 
identification of factors influencing human hematopoiesis. 
The generation of the 3D microenvironments was performed by differentia-
tion of primary BM-derived human MSCs on ceramic materials within a per-
fusion bioreactor. Human MSCs were first cultured one week in proliferative 
medium (PM) to increase cell number and ensure scaffold colonization, fol-
lowed by three weeks of osteogenic medium (OM) supplementation to pro-
mote cell differentiation while stimulating ECM production. The resulting tis-
sue was defined as “engineered niche” (eN) while naked ceramic (Ce, not 
containing hMSC but loaded with CD34+ cells) was used as internal 3D cul-
ture control. 
To characterize the composition of retrieved HSPCs, flow cytometric quantifi-
cation of cellular distribution regarding stem and progenitor cells was per-
formed (Figure 15A). Moreover, the functionality of retrieved CD34 purified 
HSPCs was tested in vitro by colony formation (Figure 15B) and in vivo by 
xenotransplantation into NSG mice (Figure 15C+D). Indeed, these cells were 
able to form colonies and to repopulate NSG mice demonstrating as proof of 




Figure 15. Engineered 3D microenvironments allow the maintenance/expansion of func-
tional HSPCs. (A) The engineered niche (eN) supports the expansion of phenotypic HSPCs, 
HSCs, multipotent progenitors (MPPs) and multipotent lymphoid progenitors (MLPs), as 
assessed by quantitative flow cytometry analysis post-3D culture. Data from n≥8 biological 
replicates are shown. Ce: ceramic only. (B) Improved maintenance of colony forming poten-
tial of eN versus Ce cultured CD34+ cells. GEmM: Colony-forming unit-Granulocyte, 
Erythroid, macrophage, Megakaryocyte. GM: Colony-forming unit-granulocyte and macro-
phage. BFU-E: Burst- forming unit-erythroid. Summarized data from n≥9 biological replicates 
are presented. (C-D) The long-term repopulation capacity of eN and Ce cultured CD34+ cells. 
Uncultured CD34+ cells served as positive control. Data from n≥4 biological replicates are 
displayed. (C) Reconstitution of the human blood compartment (% of human CD45+ cells in 
mononuclear cells) in NSG mice is shown by flow cytometry analysis of peripheral blood. (D) 
Human CD34+ cells cultured on eN and Ce also robustly engrafted in the bone marrow and 
spleen of transplanted mice, as assessed by flow cytometry 28 weeks post- transplantation. A 
Mann-Whitney U Test (for not normally distributed data) or students t-test (for normally dis-






Taken together, this system can be used to expand and analyze HSPCs in vitro 
and could also be adapted to recapitulate pathological situations such as leu-
kemia. For example, the use of human MSCs and/or HSPCs harvested from 
patients suffering from leukemia can offer the opportunity to model the dis-
ease in vitro, in an entirely human and ideally personalized setting with niche-
interactions. This could represent a powerful tool with wide range of applica-
tions, from the identification of factors deregulating niche or blood functions, 
to the screening of drugs to predict patient-specific response to defined treat-
ments without the need of an experimental model.  
 







In summary, we have developed and optimized an in vivo xenotransplanta-
tion model to study human primary AML samples from different genetic 
backgrounds, which represents a powerful tool in AML research. This model 
enables investigations regarding leukemia kinetics in dependency of the spe-
cial AML subtype and risk group, further characterization of extrinsic (e.g. 
catecholamines) and intrinsic (e.g. CDX2) factors regulating leukemogenesis, 
and studies on the effects of treatments with chemotherapy, NK cells, PARP1 
and WNT modulators on in vivo leukemogenesis and LSC subpopulations. 
 
However, this model is still limited e.g. due to the artificial situation of im-
munosuppression in mice and for example focusing on the niche regulations 
by WNT signaling cannot depict the various possible microenvironmental in-
terplays, but shows at least one mechanism how AML cells conquer the 
healthy HSC niches. More efforts to understand the far-reaching interconnec-
tions of AML cells, healthy HSCs, immune and niche cells are necessary to get 
more insights and possible targets to develop new therapeutic agents in re-
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Abstract 
Patients with acute myeloid leukaemia (AML) often achieve remission yet 
subsequently die of relapse1. Disease is driven by therapy resistant leukaemic 
stem cells (LSCs)2-4,5 which, to induce cancer, must also escape immune sur-
veillance 6. Interactions between patient LSCs and immune cells are poorly 
understood because human LSCs are studied upon transplantation into mice 
that lack a competent immune system.7 Here we demonstrate that stemness 
and immune escape are closely intertwined. Ligands of the danger detector 
NKG2D, a critical mediator of anti-tumour immunity by cytotoxic lympho-
cytes such as natural killer (NK) cells, are generally expressed on bulk AML 
cells but not on LSCs. NKG2D ligand (NKG2DL) expressing AML subpopula-
tions are efficiently cleared by NK cells in vitro and in 
NOD/SCID/IL2Rγnull (NSG) mice co-transplanted with NK cells, whereas 
NKG2DL negative counterparts isolated from the same patients escape NK 
cell killing. These NKG2DLneg AML subpopulations furthermore display 
stemness characteristics including immature morphology, stem cell specific 
gene signatures, enhanced in vitro clonogenicity and selective abilities to initi-
ate leukaemia and to survive chemotherapy in NSG mice. Mechanistically, 
enhanced levels of poly-ADP-ribose polymerase 1 (PARP1) suppress 
NKG2DL surface expression in LSCs, which in turn can be induced upon 
PARP1 inhibition (PARPi). Co-treatment with PARPi and NK cells, but not 
with PARPi or NK cells alone, suppresses leukaemogenesis in patient-derived 
xenotransplantation models. In patients with AML, low surface NKG2DL as 
well as high PARP1 expression associate with inferior clinical outcome. 
In summary, our findings that LSCs benefit from NKG2D-associated immune 
privilege driven by PARP1 uncover a novel method for LSC isolation and an 
unrecognised and targetable mechanism for sensitizing LSCs to immune con-
trol. They also provide a conceptual framework for the integration of two cen-
tral hypotheses of cancer development – the concepts of cancer stem cells and 
immune escape.  
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Despite decades of research, AML still shows high mortality rates dependent 
on genetic drivers and patient age. Different types of LSCs have been identi-
fied and were shown to mediate chemotherapy-resistance and disease recur-
rence, known as the main obstacles to cure in AML.1,2-4,5  
Here we demonstrate that LSCs also selectively evade immune surveillance 
mediated by NKG2D8. This danger detector is expressed by cytotoxic lym-
phocytes including NK cells and recognizes stress-induced ligands 
(NKG2DL) of the MIC and ULBP protein families on target cells9. We 
screened 175 AML patients (Supplementary Table 1) for individual NKG2DL 
expression (MICA, MICB, ULBP1 and ULBP2/5/6, Extended Data Fig. 1). In 
addition, we used an NKG2D-Fc chimeric protein for simultaneous detection 
of these and potentially yet unknown NKG2DL9. Beyond the reported varia-
tion in NKG2DL patterns among different AML cases10, we detected profound 
heterogeneity in NKG2DL expression on AML cells from individual patients 
(Fig. 1a and Extended Data Fig. 1). Analyses of NKG2DLpos and NKG2DLneg 
AML subpopulations sorted from the same patient (Fig. 1b-c) revealed that 
NKG2DLneg AML cells were smaller with less granularity and lower cell to 
nucleus size ratio (Fig. 1d-f and Extended Data Fig. 2a-b). Furthermore, they 
showed enhanced in vitro clonogenicity when compared to NKG2DLpos coun-
terparts (39±47 colonies vs. 1±4, p<0.001, Fig. 1g and Extended Data Fig. 3). 
Supporting their stem cell-like properties, only NKG2DLneg AML subpopula-
tions, but not corresponding NKG2DLpos cells isolated from the same samples, 
induced leukaemia in NSG mice. These leukaemias manifested by infiltration 
of bone marrow (BM) and other organs with human AML cells as detected by 
multicolour flow cytometry (NKG2DLneg, 33/35, 94%; NKG2DLpos, 0/35, 0%; 
p<0.001, Fig. 1h) and immunohistochemistry (Fig. 1i), and displayed variable 
degrees of associated illness and survival (p<0.001, Fig. 1j). Notably, 
NKG2DLneg cells generated both NKG2DLneg and NKG2DLpos progeny in en-
grafted mice (Fig. 1k-l), and sorted NKG2DLpos progeny again failed to induce 
leukaemia upon re-transplantation (Supplementary Fig. 1). NKG2DLpos AML 
cells showed a 10-fold reduced ability to home to the BM compared to 
NKG2DLneg cells (0.001±0.002% vs. 0.01±0.009 leukaemic among mouse BM 
cells, p<0.001, Fig. 1m), but also failed to engraft when transplanted directly 
into the BM by intra-femoral injection (Supplementary Fig. 2). Finally, in vivo 
treatment of mice engrafted with human AML cells with cytarabine (Fig. 1n) 
reduced mouse BM infiltration with NKG2DLpos (p<0.001) but not with 
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NKG2DLneg AML cells (Fig. 1o-p), which indicates that latter are more re-
sistant to chemotherapy. Molecularly, comparative gene expression array and 
qRT-PCR analyses revealed enrichment of established hematopoietic stem cell 
(HSC) LSC11 and 17-gene stemness signatures12 in NKG2DLneg versus 
NKG2DLpos AML subpopulations, whereas the common lineage-committed 
progenitor signature11 was instead enriched in NKG2DLpos fractions (Fig. 1q 
and Supplementary Fig. 3). As revealed by next generation sequencing, these 
differences did not result from intra-patient variation in leukaemia-specific 
mutations in NKG2DLneg versus NKG2DLpos AML cells (Fig. 1r). Together, 
these data collected in experimental systems devoid of NK cell interactions 
demonstrate that functionally defined primary human AML LSCs lack 
NKG2DL surface expression, display resistance to chemotherapy and can be 
prospectively isolated from patients using an NKG2D-Fc chimeric protein. 
Moreover, most if not all leukaemia-initiating activity within primary human 
AML samples is contained in the NKG2DLneg subpopulation. 
 
Next, we hypothesized that the absence of NKG2DL may allow LSCs to pref-
erentially evade NK cell immunosurveillance. Indeed, co-cultivation of bulk 
AML cells with polyclonal NK cells (pNKC+Mock condition) selectively re-
duced NKG2DLpos subpopulations, thereby enriching for NKG2DLneg cells. 
Importantly, this effect was abrogated by NKG2D-blockade (pNKC+anti-
NKG2D condition) (Fig. 2a-c, 7±3% vs. 82±9% compared to pre-culture condi-
tions, p<0.001). Consistently, exposure to pNKC alone or pNKC+mock result-
ed in enrichment of AML cells with increased clonogenicity (Fig. 2d, 1.7 ± 
0.20-fold versus 1.091 ± 0.15-fold, p<0.001). To confirm enriched LSC activity 
in vivo, identical numbers of AML cells retrieved from in vitro pNKC+mock or 
pNKC+anti-NKG2D co-cultures were transplanted into NSG mice, which lack 
endogenous NK cell activity13,14 and thus allow assessment of in vivo leukae-
mia development in an environment devoid of NK cell immune surveillance. 
At the time when leukaemic engraftment was uniformly detected in the BM 
and peripheral blood (PB) of mice transplanted with pNKC+mock derived 
AML cells (18/18 mice engrafted/transplanted mice, 6/6 AML cases), no (15/18 
mice, 5/6 AML) or clearly lower (3/18 mice, 1/6 AML) engraftment was ob-
served in mice receiving AML cells derived from pNKC+anti-NKG2D condi-
tions (Fig. 2e). These data indicate that, within the transplanted population of 
fixed size, cells derived from pNKC+mock conditions contain higher numbers 
of LSCs due to elimination of non-leukaemogenic NKG2DLpos cells by the 
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functional NK cells. This effect is prevented in the pNKC+anti-NKG2D setting 
in which NKG2DLpos without LSC activity survive and dilute the NKG2DLneg 
LSCs. As expected15, some LSCs were also present in pNKC+anti-NKG2D 
conditions, from which leukaemia developed after 10±1.5 weeks longer laten-
cy (Fig. 2e-f). In line, mice transplanted with pNKC+anti-NKG2D AML cells 
showed better survival than those receiving pNKC+mock AML cells (Fig. 2g). 
Together, these data demonstrate that LSCs in fact are immune-privileged 
and not eliminated by NK cells, which preferentially target non-LSCs in a 
NKG2D-dependent manner. 
 
LSCs were reported to reside predominantly within CD34+ AML cell subpop-
ulations11, among which they can be further enriched based on CD38 negativi-
ty and surface markers such as TIM-3, CD44, CD47, CD99, CD25 or CD1233,16-
25. However, LSCs show immunophenotypic heterogeneity and profound var-
iation among patients was documented by several studies3,16-25. LSCs are par-
ticularly understudied in AML cases with low or absent CD34 expression 
(<5% CD34+ among total AML cells, termed CD34 non-expressing AML) 
which comprise about ~30% of AMLs 26,27. We analysed 55 such CD34 non-
expressing AMLs and again observed heterogeneous intra-patient distribu-
tion of NKG2DL expression on AML cells (Fig. 3a-b, Extended Data Figs. 4a 
and 5a and Supplementary Fig. 4). As in CD34 expressing AMLs (Fig. 1g-j), 
also in CD34 non-expressing AMLs NKG2DLneg subpopulations showed high-
er clonogenicity (38±34 colonies versus 0.7±2, p<0.001, Fig. 3c) and selective in 
vivo AML engraftment (33/35 versus 0/35 engrafted/transplanted mice, 
p<0.001, Fig. 3d) when compared to corresponding CD34-NKG2DLpos AML 
cells isolated from the same patient. RNAseq analyses revealed enrichment 
for HSC and LSC signatures and the 17-genes AML stemness score in CD34-
NKG2DLneg subpopulations (p<0.001, Fig. 3e)11,12. These data provide molecu-
lar and functional evidence that absence of NKG2DL surface expression iden-
tifies LSCs in patients suffering from CD34 non-expressing AML and high-
light NKG2D-Fc staining as a method to prospectively isolate LSCs irrespec-
tive whether they express CD34 or not. 
 
Next, we explored the absence of NKG2DL as LSC marker in the subgroup of 
CD34 expressing AMLs. The CD34+ subpopulations containing LSCs (Sup-
plementary Fig. 5) displayed lower NKG2DL expression when compared to 
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CD34- (non-stem) AML subpopulations of the same patients (Fig. 3f-h and 
Extended Data Figs. 4b and 5b). Moreover, higher numbers of samples con-
taining >90% NKG2DLneg AML cells and higher percentages of NKG2DLneg 
AML cells in general were detected in CD34+CD38- compared to CD34+CD38+ 
and CD34- subpopulations (p<0.001, Fig. 3i-j), confirming the inverse correla-
tion between NKG2DL expression and stemness. Consistent with the notion 
that not all CD34+ AML cells are LSCs, CD34+NKG2DLpos populations were 
also detected (Fig. 3f-g and Extended Data Fig. 4b and 5b). In AML samples 
displaying ubiquitous CD34 expression (Fig. 3k-l), lack of NKG2DL separated 
stem-like immature CD34+NKG2DLneg subpopulations with clonogenic and in 
vivo leukemogenic properties from non-clonogenic, non-leukemogenic 
CD34+NKG2DLpos cells (Fig. 3m-n and Extended Data Fig. 2c). Similar associa-
tions were observed for other markers reported to identify LSCs in CD34 ex-
pressing AML (e.g. GPR56, CD1333,16-25) (Extended Data Fig. 6). 
 
To gain mechanistic insights into the cellular pathways associated with ab-
sence of NKG2DL expression in LSCs, we compared NKG2DLneg and corre-
sponding NKG2DLpos subpopulations isolated from ten genetically and phe-
notypically heterogeneous AML patients by gene expression arrays and 
RNAseq (see Supplementary Tables 2-4). We identified 22 commonly differ-
entially regulated genes, among which the recently reported LSC and HSC 
molecule GPR5628-30 and PARP1 were higher expressed in NKG2DLneg cells 
(Fig. 4a and Supplementary Table 5). PARP1 was further analysed because of 
its known involvement in the DNA damage response, which is a process (i) 
linked to NKG2DL induction31 and (ii) influenced by differentiation state32. 
Furthermore, PARP1 was shown to regulate transcription, chromatin remod-
elling and stem cell pluripotency33,34. Finally, PARP1 is a pharmacologically 
tractable candidate, and respective inhibitors were reported to influence 
apoptosis, senescence, cell cycle and differentiation in AML cells35, especially 
when applied together with chemotherapy36, hypomethylating agents37-40, te-
mozolamide41,42 or vitamin C43. 
 
Immunoblotting confirmed increased PARP1 protein expression in 
NKG2DLneg versus NKG2DLpos and CD34+ versus CD34- AML subpopulations 
within the same patients (Fig. 4b, Extended data Fig. 7 and Supplementary 
Table 6). PARP1 inhibition (PARPi) using three different PARP1 siRNAs (Fig. 
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4c-d and Supplementary Fig. 6) or the PARP1 inhibitor AG-1436144 (Fig. 4e-f, 
Supplementary Table 7 and Extended Data Fig. 8a-b) induced NKG2DL sur-
face expression on in vitro cultured AML cells, specifically fostering the emer-
gence of CD34+NKG2DLpos but not CD34-NKG2DLpos cells. These effects are 
unlikely to result from selective survival of CD34+NKG2DLpos compared to 
CD34-NKG2DLpos counterparts within the same AML sample, since no con-
sistent differences in viability, growth and apoptotic responses were observed 
when sorted populations were treated separately (Extended Data Fig. 9). Fur-
thermore, treatment with AG-14361 or the alternative PARP1 inhibitor velipa-
rib also induced NKG2DL surface expression on purified, separately treated 
NKG2DLneg AML cells (Fig. 4g-h and Extended Data Fig. 10 c). In contrast, 
treatment with 5-azacytidine, a clinically used DNA methyltransferases inhib-
itor previously reported to up-regulate NKG2DL45, only enhanced CD34-
NKG2DLpos non-LSCs but not CD34+NKG2DLpos subpopulations (Extended 
Data Fig. 10a). Other drugs associated with NKG2DL induction including all-
trans retinoic acid, or valproic acid showed no significant effects on NKG2DL 
expression in our analyses (Extended Data Fig. 10b).  
 
NKG2DL are regulated both transcriptionally and post-transcriptionally (e.g. 
by shedding from the cell surface46). Although differential in vivo shedding 
cannot be excluded, similar NKG2DL release was observed with cultured 
CD34+ LSC-enriched subpopulations versus corresponding CD34- non-LSCs 
sorted from the same patient samples (Extended Data Fig. 11). In contrast, 
increased NKG2DL mRNA expression was detected by qRT-PCR in sorted 
NKG2DLpos AML cells versus NKG2DLneg subpopulations (Extended Data 
Fig. 12), suggesting differential transcriptional regulation of NKG2DL in LSC 
compared to non-LSCs. Importantly, treatment with either PARP1 siRNAs or 
AG-14361 robustly induced NKG2DL mRNA expression between 6 and >50 
fold (Fig. 4i and Supplementary Fig. 7). Moreover, PARP1 binding sites were 
identified by in silico analysis in NKG2DL promoters (Supplementary Fig. 8), 
and binding was confirmed by chromatin immunoprecipitation in the pro-
moters of MICA and MICB (Fig. 4j). Together, these data suggest selective 




Given that NKG2DL expression on non-stem AML cells sensitizes these AML 
subpopulations to NK cell attack, and that PARPi can induce NKG2DL on 
LSCs, we hypothesized that PARPi should sensitize LSCs to in vivo lysis by 
co-transplanted NK cells. Indeed, when AML cells were pre-treated with AG-
14361 and co-transplanted together with pNKCs into NSG mice (Extended 
Data Fig. 13a-b), co-treatment with AG-14361 and pNKC strongly reduced 
leukemic cell burden at all analysed sites when compared to control settings. 
This suggests that indeed PARPi exposed AML cells are better lysed by NK 
cells. The modest reduction observed in cells treated with AG-14361 alone 
(Extended Data Fig. 13b) points to potential cytotoxic (NK cell/NKG2D-
independent) effects of PARPi, consistent with the reported single agent anti-
leukemic activity reported for PARP inhibitors35. Next, NSG mice were trans-
planted with human AML cells and then treated in vivo with AG-14361 fol-
lowed by transfer of pNKCs. We found that both the leukemic burden and 
the number of mice showing long-term AML engraftment were strongly re-
duced in mice co-treated with AG-14361 plus pNKCs, but not in animals re-
ceiving AG-14361 or pNKCs alone (Fig. 4k-l). The anti-leukemic effects in the 
co-treatment group were mediated via NKG2D, since they were abrogated by 
NKG2D blockade (AG-14361 + blocked pNKCs, Fig. 4l). These data unravel 
that the combination of PARPi and NK cells mediate synergistic anti-leukemic 
effects. Of note, in our experimental settings the treatment of AML cells with 
AG-14361 was performed before pNKC transfer. The reported results are thus 
independent of reported stimulatory effects of PARPi on NK cells 
themselves47. In conclusion, our data strongly suggest that PARP1 expression 
on AML stem cells represses NKG2DL expression mediating their NKG2D 
dependent immune escape thereby promoting LSC survival, disease progres-
sion and relapse. 
 
Indeed, in the patient cohort analysed in our study, NKG2DL surface expres-
sion inversely associated with clinical AML aggressiveness as documented (i) 
by molecular characteristics (ELN risk group AML48: p=0.01, inv(16) versus 
other: p=0.028), (ii) by rate of complete remission after induction chemothera-
py (all patients: p=0.002, patients <65 years: p=0.004) and (iii) by overall sur-
vival rates (patients <65 year: p=0.028)48 (Fig. 4m-o and Extended Data Figs. 
14-16), while no associations were observed with age or leukaemic cell counts 
(Supplementary Fig. 9). Furthermore, high PARP1 expression in leukaemic 
cells associated with poor clinical outcome in a cohort of 179 AML patients 
 92 
(p=0.0038, Fig. 4p) as revealed upon retrospective analysis of the TCGA data-
base (http://cancergenome.nih.gov)49. 
 
Extensive work particularly on NKG2D pointed out that beyond infections, 
immune surveillance indeed extends to cancer8,50. The mechanisms allowing 
cancer cells to thrive despite the existence of NKG2D and other immune sur-
veillance systems include defects in NK cells51,52 and adaptations to the tu-
mour microenvironment53. Tumour cell-intrinsic immune escape mechanisms 
such as inhibitory microRNAs e.g. down-regulating NKG2DL54 or shedding 
of NKG2DL46 also play a role, but selective effects in subpopulations of ma-
lignant cells are still elusive. Here we provide molecular, cellular and func-
tional in vivo evidence that LSC activity associates with immune evasion. Our 
data demonstrate that LSCs escape immune-surveillance due to an intrinsic 
lack of NKG2DL expression. Thus, NKG2DLneg LSCs selectively survive and 
can cause leukaemia relapse even when NK cell functionality is restored (e.g. 
upon allogeneic stem cell transplantation, SCT). This is of particular relevance 
since adoptive transfer of NK cells for AML treatment is currently intensively 
evaluated for the treatment of AML in clinical trials (see 
https://clinicaltrials.gov/ct2/results?cond=Acute+Myeloid+Leukemia&term=NK&cntry1
). Therapies aiming at installing NKG2DL expression on LSCs, like PARPi identified 
in our study, may thus represent a novel therapeutic strategy to target LSCs in vivo.  
 
While the existence of LSCs is well documented, a precise and generally ap-
plicable immune phenotypic profile of this cellular subpopulation remains 
elusive. For example, LSCs were reported to reside in CD34+CD38- AML sub-
populations, but CD34+CD38+ and CD34- LSCs were also documented3,26,27. 
Within CD34+CD38- subpopulations, additional markers were reported to en-
rich LSCs but however are not robustly expressed in all AML cases and were 
not further tested in combination. Absence of NKG2DL expression may con-
stitute a universal novel LSC marker because it reflects a major functional 
property of LSCs, namely the newly identified capacity to preferentially 
evade immune surveillance. As shown by our data collected in 175 patient 
samples, the vast majority of analysed AML cases (n=175 AML, Fig. 1a) do 
contain NKG2DLneg AML subpopulations and absence of NKG2DL expres-
sion indeed identifies functionally and molecularly defined LSCs in AMLs of 
various genetic and phenotypic background. Future studies will elucidate 
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whether co-staining with NKG2D-Fc chimeric protein and previously report-
ed LSC markers can even more precisely define LSCs. Notably, reduced NK 
cell lysis was observed for CD44(high)CD24(low) stem-like ovarian carcinoma 
cells55,56, and down-regulation of NKG2DL was described for metastatic breast 
carcinoma cells57 and in a glioma cell line model58. Stemness-associated im-
mune privilege may thus extend to other cancers and very well involve mul-
tiple mechanisms beyond NKG2D. Follow-up studies will investigate wheth-
er stemness-associated immune escape may be a general principle in neo-
plasia and whether absence of NKG2DL expression can identify cancer stem 
cells also in other types of leukaemia and solid tumours. 
 
The selective suppression of NKG2DL expression on LSCs may reflect their 
resemblance to their cells of origin, the healthy hematopoietic stem and early 
progenitor cells (HSPCs). Although non-malignant hematopoietic cells in general 
lack NKG2DL expression, NKG2DL are particularly absent on the surface of CD34+ 
HSPCs59 (Fig. 4e-f and Extended Data Fig. 17) whereas low percentages of 
NKG2DLpos cells can be detected within more differentiated subpopulations, particu-
larly upon activation or exposure to cellular stress60-62. In line, a gradual inverse 
correlation between NKG2DL expression and stemness is also noted in AML, 
as indicated by the intermediate clonogenicity observed in NKG2DLinterm AML 
cells when compared to corresponding NKG2DLneg and NKG2DLpos subpopu-
lations (Extended Data Fig. 3), and the reduced percentages of NKG2DLneg 
AML cells in CD34+CD38- subpopulations versus CD34+CD38+ and CD34- 
AML subpopulations (Fig. 3i-j).  
 
Our findings that PARP1 expression precludes NKG2DL expression in LSCs 
are of particular interest as PARP1 inhibitors are under clinical investigation63 
and appear to be well-tolerated in patients42,64-66. This is consistent with our 
data showing that short-term in vivo treatment with AG-14361, while suffi-
cient to up-regulate NKG2DL on engrafted human AML cells (Extended Data 
Fig. 8c-d), did not cause overt hematopoietic toxicity nor lead to cell death or 
NKG2DL induction on healthy hematopoietic cells (Extended data Fig. 18). At 
advanced disease stages of AML, immune surveillance is disturbed by multi-
ple mechanisms beyond those affecting NKG2DL expression. Thus, the im-
mune-sensitizing effect of PARPi on LSCs unravelled by our study may be 
particularly well exploited when respective drugs are applied in the context 
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of a functionally restored immune system, e.g. at minimal residual disease 
stage and/or in conjunction with SCT or allogeneic NK cell therapies. In con-
clusion, PARP1 inhibition indeed holds promise to specifically target LSCs 
and to facilitate immune-mediated long-term cure in AML. 
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Figure 1: Absence of immunostimulatory NKG2DL enriches for chemotherapy resistant 
LSCs. (a) Flow cytometry analysis showing percentages of NKG2DLneg (red) and NKG2DLpos 
(blue) AML cells within individual patients. (b-m) NKG2DLneg and NKG2DLpos AML sub-
populations isolated from the same patients were analyzed side-by-side at equal numbers. 
Schematic overview (b), representative examples of gating strategies (c), forward/sideward 
scatter plots (d), and comparison of sorted cells by May-Grünwald-Giemsa staining (e: exem-
plary pictures; f: quantification of cell to nucleus size ratio, 50 cells quantified for each sub-
population and AML sample, #1, 3, 4, 5, 57), in vitro colony assays (g: #1-32, means of tech-
nical triplicates; note that in 81% of cases colonies exclusively emerged from NKG2DLneg 
cells) and transplantation assays into NSG mice (h: summarized results on long-term infiltra-
tion with human leukaemic cells in mouse PB, BM and organs as detected by multicolor flow 
cytometry for human leukemic antigens, each dot represents one mouse, #1, 6-12, 33-34; i: 
representative BM histopathology pictures, left: H&E, right: anti-CD33, 630x magnification; j: 
Kaplan-Meier survival analysis; 4-5 mice per cellular subpopulation and patient; #1,6-8,12; k: 
representative and l: summarized results comparing NKG2DLneg and NKG2DLpos cell per-
centages in engrafted mouse-derived AML cells, post-tx, versus corresponding patient-
derived pre-transplant (pre-tx) AML cells, #1, #6-8, n=3-4 mice per patient and subpopulation; 
m: homing asssays showing summarized percentages of CFSE-labeled cells homed to the BM, 
each dot represents one mouse, n=3 mice per subpopulation and patient, #35-37). (n-p) Effect 
of in vivo cytarabine treatment (1 mg/day s.c. for 2-4 days) on mouse BM leukaemic burden 
and percentages of NKG2DLneg and NKG2DLpos within infiltrating AML cells, (n: schematic 
overview, BM before treatment collected by BM puncture; o: exemplary flow cytometry plots; 
p: summarized results for NKG2DLneg (left) and NKG2DLpos (right) AML subpopulations (#9, 
#42, #72, #76, #99, #118, #125 and #174; dots connected by one line depict results collected 
before and after treatment in one animal). (q-r) LSC, HSC, common lineage-committed pro-
genitor1 and 17 genes stemness score2 signatures and leukaemia-specific mutations (q: gene 




Figure 2: NK cells preferentially lyse non-LSCs. AML cells co-cultured +/- pNKCs and iso-
type control (mock+pNKCs, red) or blocking anti-NKG2D F(ab’)2 6H7 (anti-NKG2D+pNKCs, 
blue) were analyzed by flow cytometry and in functional assays. (a) Schematic overview, (b-
c) flow cytometry analysis (b: representative results, c: quantification indicating the ratio of % 
NKG2DLpos cells in different treatment groups relative to corresponding cells analyzed prior 
to culture (#13, 36, 43; p<0.001; Students t-test). (d) Quantification of colony numbers (#9-10, 
13-17, 35-36, means of technical triplicates) and (e-g) in vivo engraftment in NSG mice of AML 
cells separated from the different co-culture conditions (#9, #10, #13, #14, #17, #35; e-g: n=3 
mice per AML sample and condition, each dot or square represents one mouse). Mice trans-
planted with AML cells derived from mock+pNKCs (red) or anti-NKG2D+pNKCs (blue) co-
cultures were routinely screened13 by flow cytometry in PB and BM (by BM puncture); if en-
graftment was detected, all mice transplanted with cells of the same sample were analysed 
for engraftment in BM (e, left) and PB (e, right)13; mice lacking engraftment at this time-point 
(all from anti-NKG2D+pNKCs conditions) were further followed and shown to engraft later 
(f, full squares: murine BM, empty squares: murine PB). Note that all AML showed engraft-
ment, albeit at variable time-points. g: Kaplan-Meier survival analysis. (* p < 0.05, ** p < 0.01, 








































































































































































































































































































































Figure 3: Absence of NKG2DL identifies LSCs independently of CD34 expression. (a-e) 
CD34 non-expressing AMLs: flow cytometry analysis (a: exemplary results; b: individual 
results from n=55 patients, see also Supplementary Table 1) and (c-e) comparison of 
NKG2DLneg and NKG2DLpos AML cells sorted from the same patients with respect to colony 
formation (c: #1, 6, 9-11, 33-34, mean of technical triplicates performed for each patient and 
subpopulation), in vivo engraftment in NSG mice (d: percentages of human leukaemic among 
murine BM cells; each dot represents one mouse; n=3-5 mice per subpopulation and AML 
case, #9-11, 33-34), and LSC, HSC and 17-gene signatures (e: biological triplicates for each 
subpopulation and patient; #9-11, 33-34). (f-j) CD34 expressing AMLs: flow cytometry analy-
sis (f: exemplary results, g:  individual results from n=98 patients, see also Supplementary 
Figure 4 and Supplementary Table 1, h: quantification of % NKG2DLneg cells in CD34+ and 
CD34- subpopulations, i: quantification of AML samples containing >90% NKG2DLneg cells 
within CD34+CD38-, CD34+CD38+ and CD34- subpopulations and j: quantification of 
NKG2DLneg cells within these subpopulations). (k-n) AML with ubiquitous CD34 expression: 
flow cytometry analysis (k: exemplary results, l: individual patient results) and comparison 
of colony formation (m, #57, 111, 168, all in triplicates) and in vivo engraftment in NSG mice 
(n; each dot represents one mouse, n=3 mice per subpopulation and patient, #5, 111, 168) from 
CD34+NKG2DLneg and CD34+NKG2DLpos AML cells sorted from the same patients. (* p < 0.05, 








Figure 4: Increased PARP1 expression in LSCs contributes to their selective escape from 
NK cell immune surveillance. (a) Overlap of differentially regulated genes in NKG2DLneg 
versus NKG2DLpos cells isolated from the same AMLs and analysed by gene expression ar-
rays (#1,6-8, 12; right panel) and RNA sequencing (#9-11, 33-34; left panel). (b) Exemplary 
immunoblots showing PARP1 protein expression (loading control: actin) in sorted 
NKG2DLneg and corresponding NKG2DLpos AML subpopulations (cropped images are 
shown, for additional patients and full images see Extended Data Fig. 7 and Source Data File 
1). (c-j) In vitro PARP1 inhibition in bulk AML cells. Shown are flow cytometry analyses after 
treatment with PARP1 versus control siRNAs (c: exemplary results, #42; d: summarized re-
sults, #36-37, 42, 151), and PARP1 inhibitors (AG-14361, 20 µM; veliparib, 10 µM) versus 
DMSO (0.2%) as carrier control (e: exemplary results; f: summarized results, each dot, square 
or triangle represents the average of technical triplicates from one subpopulation in one 
AML, left panel: #2, 16-18, 27, 29-30, 35-36, 38-39, 40-42, 47, 82, 100, 148, or healthy cord blood, 
right panel: n=3 donors). (g-h) In vitro PARP1 inhibition in sorted NKG2DLneg AML cells us-
ing AG-14361 (20 µM) or Veliparib (1 µM) versus DMSO carrier control (0.2%) (g: schematic 
procedure with representative results; h: quantification of NKG2DLpos cells post-treatment; 
each dot represents the average of technical replicates obtained from one AML case; #16, 35-
37, 151). (i) Bulk AML cells were treated with PARP1 versus control siRNAs (#4, 151), or with 
AG-14361 (20 µM) versus DMSO control (#36, 37, 151). Shown are summarized relative 
mRNA data of single NKG2DL from PARP1 inhibition versus control conditions (see Sup-
plementary Figure 7 for results on single NKG2DL). (j) ChIP analysis illustrating direct re-
cruitment of PARP1 to the MICA and MICB promoter (#35-37, biological triplicates). (k-l) 
Leukemia development in NSG mice transplanted with AML cells and treated with AG-14361 
or DMSO +/- pNKC (k: schematic illustration of experimental setup; l: summarized flow cy-
tometry data in PB, BM and organs, each dot represents one mouse; n=7-16 mice per condi-
tion, #42) (m-o) Correlation of NKG2DL surface expression and clinical AML characteristics 
(all patients with AML at first diagnosis, APL excluded, n=175; n: genetic and molecular 
characteristics; o: achievement of complete remission (CR) or incomplete CR (CRi) after in-
duction chemotherapy, p: and overall survival). (p) Survival analysis of AML patients with 
enhanced (above median) versus low (below median) PARP1 (TCGA, n=179 patients23). (* p < 
0.05, ** p < 0.01, *** p < 0.001)  
For all Figure legends: if not mentioned otherwise, a Mann-Whitney U Test was performed 
for statistical analysis.  
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Primary AML cells and blood samples of healthy donors 
Peripheral blood mononuclear cells (PBMC) cells of patients with AML or 
healthy donors were isolated by density gradient centrifugation after in-
formed consent in accordance with the declaration of Helsinki. Cells were 
viably frozen (in RPMI1640, Sigma-Aldrich, St. Louis, MO, USA, supplement-
ed with 20% FCS, Sigma-Aldrich and 10% dimethyl sulfoxide solution, Ap-
pliChem, Darmstadt, Germany) and freshly thawed for each experiment. For 
AML samples containing <95% leukemic cells, leukemic cells were enriched 
by MACS or FACS sorting for leukemic antigens (see Supplementary Table 1) 
prior to use. Post-sort purity was routinely above 95%. Patient characteristics 
are summarized in Supplementary Table 1. Cord blood CD34+ cells were iso-
lated from healthy full-term deliveries by ficoll gradient, further purified us-
ing the indirect CD34 microbead kit from MACS (Miltenyi, Bergisch-
Gladbach, Germany) and frozen in fetal calf serum (FCS) containing 10% di-
methyl sulfoxide solution. The study was conducted according to the guide-
lines of the Eberhard-Karls-University Tuebingen, the Ethikkomission Nord-
west- und Zentralschweiz and the DKFZ and University of Heidelberg Ethics 
committees. Informed consent was obtained from all patients included in the 
study. 
 
Flow cytometry and sorting into NKG2DLneg and NKG2DLpos cells 
For flow cytometry analyses, fluorescence conjugates targeting human CD33, 
CD34, CD133, CD117, CD45, CD44, CD123, CD99, CD96, CD25 and TIM3 (BD 
Biosciences, Franklin Lakes, NJ, USA), CD14, CD13 (eBiosciences, San Diego, 
CA, USA), CD3 and CD19 (Biolegend, San Diego, CA, USA) were used, and 
analysis was performed on either a FACS CantoII or LSR II Fortessa (both BD 
Biosciences) or Cytoflex (Beckman Coulter, Brea, CA, USA). SytoxBlue or 7-
AAD was used for live and dead cell discrimination. 
For simultaneous staining of all NKG2DL, a recombinant NKG2D-Fc chimera 
(fusion protein) and the corresponding isotype control were purchased from 
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R&D (Minneapolis, MN, USA) and biotinylated with the One-step biotinyla-
tion kit (MACS Miltenyi) according to manufactures instructions. Prior to 
staining, cells were blocked with human IgG (Sigma-Aldrich) and washed. 
Then biotinylated fusion protein or control (10µg/ml each) were added fol-
lowed by streptavidin-PE (LifeTechnologies, Carlsbad, CA, USA) and selec-
tion antibodies. In some cases, AML cells were stained with non-biotinylated 
fusion protein as described above except that cells were not blocked and PE-
anti-human IgG1 (SouthernBiotech, Birmingham, AL, USA) was used as sec-
ondary reagent. 7-AAD was used to exclude dead cells, and sorting was per-
formed using a FACS Aria III or FACSFusion (both BD Biosciences). Post-sort 
purity was routinely >95%. 
For staining of individual NKG2DL, previously described antibodies against 
human MICA, MICB, ULBP1 and ULBP2/5/6 or isotype control (all at 
10µg/ml) followed by goat anti-mouse–PE F(ab')2 fragments (Dako) were used 
as described above. 
For all analyses log scale ranging from 101 to 107 was used.  
 
May-Grünwald-Giemsa staining 
For morphological analyses, sorted NKG2DLneg and NKG2DLpos cells were 
spinned on poly-L-lysine coated slides (Sigma-Aldrich, St. Loius, MO, USA) 
using a Cytospin 4 (ThermoFisher Scientific, Waltham, MA, USA). After-
wards, slides were stained in May-Grünwald solution, washed, stained in 
Giemsa solution, again washed and air-dried overnight. Pictures were taken 
at 60x magnification on a Leica digital MC170 HD camera attached to a Leica 
DM 2000 LED (Leica Microsystems AG, Switzerland).  
 
Colony forming unit (CFU) assays 
For CFU assays, equal numbers of NKG2DLneg or NKG2DLpos cells sorted by 
FACS were plated in methylcellulose (Methocult H4434, StemCell Technolo-
gies, Vancouver, Canada) in triplicates, incubated at 37°C in 5% CO2 and 
scored for CFUs at day 14. Depending on the availability of patient material, 
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12.5x103 or 25x103 cells were plated per well in this assay (same numbers for 
all conditions per individual patient). 
Mice and xenotransplantation assays 
NOD.Cg-Prkdcscid IL2rgtmWjl/Sz (also termed NOD/SCID/IL2Rγnull, NSG) mice 
purchased from Jackson Laboratory (Bar Harbor, ME, USA) were maintained 
under pathogen-free conditions according to the Swiss and German federal 
and state regulations. All animal experiments were approved by the Regier-
ungspräsidium Karlsruhe (Tierversuchsantrag numbers G108/12 and 
G243/16), Tübingen (M12/12) and the Veterinäramt Basel-Stadt (24981 and 
28218). 
Freshly thawed primary AML cells were transplanted (between 4x105 and 
1x106 cells per mouse, depending on availability but in any case at equal 
numbers for all fractions derived from an individual patient) into 6-10 weeks 
old gender-matched animals with or without prior sublethal irradiation via 
the tail vein or intrafemorally1 after resuspension in 200 or 25 µl PBS, respec-
tively. AML cells were selected based on CD33+ or other pan-leukemic anti-
gen expression, depending on the AML sample. Alternatively, CD3 depletion 
was performed before cells were sorted into NKG2DLneg and NKG2DLpos cells 
and used for further experiments. Patients analyzed in individual experi-
ments are indicated in the figure or figure legend, and patient’ characteristics 
are summarized in Supplementary Table 1. Engraftment was assessed in PB 
and BM at signs of distress (e.g. decreased food and water consumption, rap-
id breathing, altered movement) or routinely every 4 to 5 weeks in one mouse 
per group for each AML case following a protocol recently published by our 
group.2 Engraftment was defined as ≥1% leukemic cells in murine PB or BM 
as assessed by multi-color flow cytometry using antibodies against human 
leukemic antigens according to the individual AML specific phenotype. Line-
age markers (CD3, CD19) were used to exclude engraftment with healthy 
hematopoietic cells. For survival analyses, mice of the experimental group 
were euthanized at sickness (weight loss, ruffled coat, weakness, reduced mo-
tility, other severe pathology, according to regulations contained in our ani-
mal protocol and the German and Swiss animal handling guidelines) and/or 
detection of heavy infiltration (>50%) with human AML among murine bone 
marrow (BM) cells as revealed by routine testing conducted every 4-5 weeks 
in at least one mouse per group.3,4 Upon detection of heavy leukemic infiltra-
tion, all mice of the corresponding group were euthanized; in case leukemia 
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was not similarly detected the respective mice were scored as lost for follow-
up in the Kaplan-Meier analysis. Upon termination of experiments, all mice 
underwent final assessment consisting of multi-color flow cytometry of PB, 
BM, liver and spleen performed as described above. Leukemic engraftment 
was further verified by whole body histopathology (see below). For second-
ary transplantations, BM cells freshly isolated from mice (taken from both 
femora and tibiae) were sorted again into NKG2DLneg and NKG2DLpos frac-
tions as described above, and used for re-transplantation at equal numbers as 
in corresponding primary transplantations.  
BALB/c mice were purchased from Charles River (Wilmington, MA, USA) 
and maintained under pathogen-free conditions according to the Swiss feder-
al and state regulations. 
 
Histopathological analysis 
For histopathological analyses, murine organs were fixed in 4% phosphate 
buffered formalin and then embedded in paraffin. Immunohistochemical 
analysis was performed as previously described, using H&E staining and an-
tibodies against human CD33 (Ventana, Tucson, Arizona, USA, Mouse mono-
clonal, Clone: QBEnd 10, RTU) and human CD34 (Ventana, Mouse monoclo-
nal, Clone: QBEnd 10, RTU).5  
 
Homing assay 
AML cells were separated into NKG2DLneg and NKG2DLpos fractions as de-
scribed above, labeled with CFSE (CellTrace CFSE Cell Proliferation Kit, 
ThermoFisher Scientific, Waltham, MA, USA) and injected at 1x106 cells per 
mouse via the tail vein in n=3 NSG mice per group and per patient. After 12 
hours, mice were euthanized and BM analyzed by flow cytometry recogniz-
ing CFSE as well as human leukemic antigens (CD33, CD34) using a LSR II 
Fortessa (BD Biosciences). 
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Microarray and quantitative real-time reverse transcription PCR (qRT-PCR) 
analyses 
Microarray gene expression analyses were performed on RNA extracted us-
ing the RNeasy Mini Kit (Qiagen) from NKG2DLneg and NKG2DLpos sorted 
patient blasts. Triplicate independent biological experiments were performed 
for each individual sample. Concentration and purity of RNA samples were 
determined with a NanoDrop photometer (peqlab), and integrity confirmed 
on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only RNA 
samples with RIN values ≥ 7.5 were considered. Per condition, 100 ng of RNA 
were used to prepare cyanine-3-labeled cRNA for hybridizations, which were 
performed according to standard protocols using Agilent SurePrint G3 Hu-
man Gene Expression 8x60K v2 Microarrays. After extensive washing, fluo-
rescence intensities were detected with the Scan Control A.8.4.1 software (Ag-
ilent) on an Agilent DNA Microarray Scanner and extracted from images us-
ing Feature Extraction 10.7.31 software (Agilent). Quantile normalization was 
applied to the data set and correlation analysis was performed. After normal-
ization, the microarray probes were filtered according to the flag information 
provided by Feature Extraction 10.7.3.1 software. Fold changes were calculat-
ed, and differentially expressed RNAs were identified accordingly. The log2-
normalized data were linearized and used as input for Gene set enrichment 
analysis (GSEA, Broadinstitute.org). One gene matrix transposed file was 
generated containing the transcripts from up- and down-regulated genes in 
the comparison of NKG2DLneg and NKG2DLpos blasts (CD34expressing and 
non-expressing AMLs separately), and the transcripts of the LSC signature, 
the HSC signature and the progenitor signature published previously6. GSEA 
computes if the gene set is enriched in the generated gene expression data. 
For qRT-PCR, the QuantiTect Whole Transcriptome Kit (Qiagen) was used for 
pre-amplification and reverse transcription of limited amounts of RNA to ob-
tain high yields of cDNA. Gene transcripts were detected using an Applied 
Biosystems® Real-Time PCR 7500 Fast System instrument and Fast Start Uni-
versal SYBR Green Master with Rox (Roche) and gene-specific primers. A 
PBGD control for equal loading was used throughout the experiments to later 
normalize the real-time PCR data. Fold change values of gene expression by 
averages from triplicate measurements were calculated using the 
∆∆CT method as described by Livak and Schmittgen7. For gene expression 
analyses, RNA was isolated using either the Promega ReliaPrepTM RNA Mini-
prep Systems (Promega, Madison, WI, USA) or the RNeasy Plus Micro Kit 
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(Qiagen) and transcribed into cDNA using the High-Capacity cDNA Archive 
Kit (Applied Biosystems, Foster City, CA, USA) or the FastStart Universal 
SYBR Green Master (ROX) (Roche). qRT-PCR was performed as detailed 
above. All primers are listed in the Supplementary Table 8. 
 
RNA-sequencing and Gene set enrichment analysis (GSEA) 
Total RNA isolation from 50,000 sorted cells was performed using an Arctu-
rus PicoPure RNA isolation kit (Life Technologies, Invitrogen) according to 
the manufacturer’s instructions. cDNA libraries were generated with 10 ng of 
total RNA using the SMARTer Ultra Low RNA kit for Illumina sequencing 
(Clontech Laboratories) according to the manufacturer’s indications. Sequenc-
ing was performed with a HiSeq2000 device (Illumina) and three samples per 
lane. Sequences were aligned to hg19 reference genome using the STAR 
alignment software8 with Gencode v19 as the transcriptome annotation. 
DESeq29 was used to generate a list of differentially expressed protein-coding 
genes between NKG2DLneg and NKG2DLpos samples. This pre-ranked list was 
used for Gene Set Enrichment Analysis (GSEA) using the GSEA desktop ap-
plication and gene sets databases downloaded from the Broad Institute using 
default settings with 2000 permutations. Calculations were performed with R 
version 3.3.1 in R-Studio (version 0.99.903). 
 
Targeted Next Generation Sequencing (NGS) for analysis of leukaemia-
specific mutations 
NGS analysis was performed on sorted NKG2DLpos versus NKG2DLneg sub-
populations from n=8 AML samples. DNA for NGS was isolated using ZR-
Duet DNA/RNA MiniPrep kit (ZymoResearch, Irvine, CA, USA) according to 
the manufacturer’s protocol and NGS analysis performed as previously de-
scribed2. Patient NGS libraries were prepared using the AML community 
panel from Thermo Fisher containing 19 genes frequently mutated in AML 
(see ampliseq.com). Patient libraries were sequenced using the Ion PGM plat-
form and analyzed using the Ion Reporter AML pipeline (version 5.0). The 
average coverage per sample was ~1.400-fold. Sensitivity for calling a muta-
tion was set at 3%. If a mutation was observed in a “post-transplantation” 
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sample but not reported to be present in the initial patient sample, the 
mapped reads were manually analyzed to assess whether the mutation was 
present but with a lower allelic burden than 3%. The sensitivity of such retro-
spective analysis is dependent on the coverage of the specific region (normal-
ly around 0.25%).  
 
In vitro co-cultures of AML and NK cells 
Polyclonal NK cells (pNKC) were generated by incubation of PBMC with 
K562-41BBL-IL15 feeder cells obtained from St. Jude's Children's Research 
Hospital as described previously10. Cultures of primary AML cells with or 
without pNKC (E:T ratio 10:1) were conducted for 16h in the presence or ab-
sence of F(ab’)2 fragments of a blocking anti-NKG2D mAb (clone 6H7 kindly 
provided by Amgen Inc.)11 or isotype control (SouthernBiotech, Clone 15H6, 
5µg/ml each). Afterwards, AML cells were retrieved by removing dead cells 
using a ficoll gradient followed by MACS (Miltenyi) selection for leukemic 
antigens expressed in the initial patient sample (see Supplementary Table 1) 
and further analyzed at equal numbers in CFU and in vivo xenotransplanta-
tion assays in NSG mice. Mice were screened by flow cytometry in PB and 
BM (by BM puncture) performed routinely in one mouse per experimental 
group; if engraftment was detected, all mice transplanted with cells of the 
same AML case (from all different experimental groups) were analysed. 
 
Immunoblot 
1x106 AML cells sorted as described above by NKG2D-Fc FACS in NKG2DLpos 
and NKG2DLneg fractions or by MACS (Miltenyi) in CD34+ and CD34- cells 
were re-suspended in Lysis Buffer (#9803, Cell Signaling, Danvers, MA, USA) 
supplemented with Protease/Phosphatase Inhibitor Cocktail (#78442 Ther-
moFisher Scientific) and disrupted by vortexing. Samples were cleared by 
centrifugation, soluble protein denatured in Laemmli buffer, 10 µg total pro-
tein separated in bis-acrylamide gels (#161-0148, BioRad, Hercules, CA, USA) 
by Disc-SDS-PAGE, and transferred onto PVDF membrane (#10600021, Amer-
sham, GE Healthcare Life Sciences, Chalfont St. Giles, UK) in a semi-dry blot-
ting apparatus (Trans-Blot Turbo, BioRad). Membranes were blocked with 
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10% nonfat dry milk (#9999S, Cell Signaling, diluted in TBS 0.1% Tween-20, 
p1379, Sigma). Proteins were stained with anti-human PARP1 (#9542S) and 
anti β−actin (#3700S) antibodies, and detected by ECL reaction using HRP-
linked secondary reagents (#7074S, anti-rabbit IgG and #7076S, anti-mouse 
IgG, all from Cell Signaling Technology, see manufacturer’s instructions).  
 
In vitro treatments with AG-14361, veliparib, azacytidine, ATRA, valproic acid 
or doxorubicine 
Bulk AML cells were cultured in RPMI1640 supplemented with 10% FCS and 
cord blood CD34+ cells respectively in X-Vivo 20 (Lonza, Basel, Switzerland) 
supplemented with 100 ng/ml SCF, 100 ng/ml TPO, 100 ng/ml Flt3-L and 60 
ng/ml IL-3 (all Peprotech, Rocky Hill, NJ, USA). Treatments with 20 µM AG-
14361 (Selleckchem, Munich, Germany) or DMSO as vehicle control were per-
formed for 24h for AML cells and respectively 48h for cord blood cells. Alter-
natively, bulk AML cells were cultured in the presence or absence of azacyti-
dine (5µM, Sigma-Aldrich), all-trans retinoic acid (ATRA, 1 µM, Sigma-
Aldrich), valproic acid (VPA, 2 µM, Sigma-Aldrich) or vehicle control for 24 
hours. 
For treatments of sorted NKG2DLneg AML cells, the latter were sorted from 
bulk AML cells as described into NKG2DLneg cells as described and then cul-
tured in the presence of either AG-14361 (20 µM), veliparib (10 µM, Selleck-
chem, Munich, Germany) or DMSO vehicle control for 24h and then analyzed 
for NKG2DL expression as described.  
For in vitro analysis of chemotherapy resistance, AML cells sorted into 
NKG2DLneg and NKG2DLpos subpopulations were separately cultured in the 
presence of Doxorubicine (10 ng/ml, Adriblastin, Pfizer, New York City, NY, 
USA) or PBS control for 24h or 48h and then analysed using AnnexinV/7-
AAD staining (BD Biosciences, Franklin Lakes, NJ, USA, according to manu-
facturer’s protocol) using a Beckman Coulter Cytoflex (Beckman Coulter, 
Brea, CA, USA).  
 
In vivo treatments with AG-14361 or cytarabine 
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For in vivo treatments with AG-14361, BALB/c mice or NSG mice engrafted 
with human AML cells (>40% of leukemic cells among murine BM or PB cells 
as assessed by BM puncture or PB analysis) were divided into two groups, 
one receiving 10 mg/kg AG-14361, the other DMSO control for 5 consecutive 
days by intraperitoneal injections as previously described12; all mice were sac-
rificed for final analysis at day 6.  
For in vivo analysis of chemotherapy resistance, NSG mice were engrafted as 
described above with bulk AML cells and leukemic engraftment screened by 
BM puncture. Upon detection of engraftment, BM was stained for leukemic 
infiltration and NKG2DL distribution on human leukemic cells. Mice were 
then treated with 1 mg/day cytarabine (Cytostar, Pfizer) for 2 to 4 consecutive 
days via subcutaneous injections and analyzed 48h later for human leukemic 




AML cells cultured in vitro as described above were transfected with Silencer 
Select small interfering RNAs (siRNAs) for PARP1 or respectively control 
siRNAs (both purchased from LifeTechnologies, Carlsbad, CA, USA) using 
Lipofectamine RNAiMAX reagent (LifeTechnologies). 24 hours later the 
transfected cells were harvested and analyzed by qRT-PCR analysis for 
knockdown efficiency and by flow cytometry for NKG2DL expression. 
Treatments were performed with three different PARP1 siRNAs (used sepa-
rately or as scrambled mix) or with a scrambled mix of two non-coding siR-
NAs as control.  
 
Analysis of healthy hematopoietic stem and progenitor cells and blood 
counts 
DMSO and AG-14361 treated BALB/c mice were sacrificed and whole BM 
(from both femora and tibiae) as well as PB were isolated and stained as de-
scribed13. For HSC staining, the following antibodies were used: anti-mouse 
lineage cocktail, anti-mouse Ly6A/E (Sca-1), anti-mouse CD117 (c-kit), anti-
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mouse CD48 and anti-mouse CD150 (all Biolegend). For progenitor staining, 
anti-mouse lineage cocktail, anti-mouse CD117, anti-mouse CD34 and anti-
mouse CD16/32 antibodies were used (all Biolegend, except CD34 eBioscienc-
es). HSCs were identified as previously described13. Murine NKG2DL expres-
sion was determined using FITC-labeled tetramers of mouse NKG2D ecto-
domains. Biotinylated murine NKG2D monomers were generated as de-
scribed before14. Tetramerization was performed with streptavidin-FITC (Life 
Technologies) in a 4:1 molar ratio as described before for human NKG2D te-
tramers15. Control tetramers were generated from biotinylated HLA-A*0201 
monomers containing influenza A virus peptide (58–66) GILGFVFTL (kindly 
provided by S. Stevanović, University of Tübingen, Germany). All samples 
were analyzed using a LSR II Fortessa (BD Biosciences). Complete blood 
counts (CBCs) were determined on an Advia120 Hematology Analyzer using 
Multispecies version 5.9.0-MS software (Bayer). 
 
Analysis of external datasets 
RSEM normalised RNA-sequencing expression data of 179 primary AML 
samples from The Cancer Genome Atlas (TCGA)16 were downloaded from the 
Broad Institute. Clinical data and mutational status were downloaded from 
the TCGA website. Samples were stratified according to PARP1 expression 
(RPKM, high=above the median, low=below the median). Survival analysis 
was performed by using the Mantel-Cox log-rank test in GraphPad Prism 7 
software. 
Raw counts of the GSE7424617 dataset was downloaded from the GEO portal. 
DESeq29 was used to generate a list of differentially expressed genes between 
LSC and Blast samples. This preranked list was used for Gene Set Enrichment 
Analysis (GSEA) using the GSEA desktop application and gene sets databases 
downloaded from the Broad Institute using default settings with 2000 permu-
tations. Calculations were performed with R version 3.3.1 in R-Studio (version 
0.99.903). 
 
In vivo killing of human AML cells by pNKC 
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For the experiments depicted in Extended Data Figure 13, bulk AML cells 
were cultured in vitro in the presence of DMSO or 20 µM AG-14361 for 24h, 
labeled with CFSE and transplanted into NSG mice which were co-
transplanted or not with pNKC (AML cells, 1.5x106; NK cells, 15x106). 12h af-
ter transplantation mice of all conditions were sacrificed and analyzed for 
human leukemic cells in BM, PB and organs by flow cytometry using a LSR II 
Fortessa (CFSE and antibody staining with CD33 and CD34, both BD Biosci-
ences). 
For the experiments depicted in Figure 4k-l, sublethally irradiated NSG mice 
were transplanted with 6x105 bulk primary AML cells/mouse at day 0. Mice 
then received either DMSO (15% in PBS) or AG-14361 (10mg/kg) via intraperi-
toneal injections from day 1 to 5 post-transplantation. At day 6 post-
transplantation, mice received either 12x106 pNK cells (untreated or pre-
treated in vitro with 5µg/ml anti-NKG2D 6H7 F(ab’)2 fragments or isotype 
control) or PBS as control via tail vein injection. Mice of all treatment groups 
were then followed for signs of sickness. Final analysis was performed in all 
mice at week 12 (experiment 1) or week 9 post-transplantation (experiments 2 
and 3) when routine BM analysis detected first robust engraftment in mice of 
the control group. In all cases, analysis consisted of multicolour flow cytome-
try for human leukemic antigens as well as human CD3 and CD19 (to exclude 
engraftment with healthy hematopoietic cells) performed using a Beckman 
Coulter Cytoflex on PB, BM, spleen and liver of all mice included in the ex-
periment. 
 
Chromatin immunoprecipitation assay (ChIP) 
ChIP was essentially performed as described by Wang et al. (2017) using 
PARP1 antibody (Cell signaling, #S9542) and the primers summarized in 
Supplementary Table 9.18 Briefly, 1 × 107 primary AML blasts were fixed in 1% 
formaldehyde, sonicated, precleared, and incubated with 10 µg anti-PARP-1 
or isotype control IgG antibodies overnight at 4°C. Complexes were washed, 
DNA-extracted, precipitated, and amplified by RT-PCR using primers sets 
homologous to regions of the human MICA or the MICB promoter. Non-




Primary AML cells were sorted by MACS in CD34+ (black) and CD34- (grey) 
populations and cultured for 72h before sMICA, sMICb, sULBP1 and sULBP2 
were analysed in supernatants by ELISA as described previously (Hilpert et 





Data represent mean ±SEM. P-values are derived via the application of the 
students t-test, Mann-Whitney U test or two-tailed Fisher’s exact test. 
 
Data availability statement 
Data that support the findings of this study will be deposited in Gene Expres-
sion Omnibus prior to publication. All other relevant data are available from 
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Extended Data Figures 
 
 
Extended Data Figure 1: Expression of single NKG2DL in primary AML samples. Flow 
cytometry analysis using antibodies against human MICA, hMICB, hULBP1 or ULBP2/5/6 in 
primary AML cells from n=62 patients. The heterogeneous expression within the same pa-
tients mirrors the results obtained upon combined analysis of all NKG2DL using NKG2D-Fc 

































               
Extended Data Figure 2: May-Grünwald-Giemsa staining of NKG2DLneg and corresponding 
NKG2DLpos AML cells (a-b) and forward/sideward flow cytometry plots indicating 
NKG2DLneg and NKG2DLpos AML subpopulations (c). Note that, irrespectively of CD34 ex-
pression, NKG2DLpos AML cells show more mature morphology (with mostly larger cell size 
and enhanced granularity) when compared to corresponding NKG2DLneg AML cells isolated 
from the same patient sample. 
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Extended Data Figure 3. Colony forming (CFU) assays of NKG2DLneg, NKG2DLinterm and 
NKG2DLpos AML cells isolated from the same patients. Shown are (a) representative flow 
cytometry plots indicating the sorting strategy (#37) and (b) summarized results from three 
AML cases as indicated (each dot or rhombus represents the result from technical triplicates 
performed with one subpopulation from one patient). Note that, in all analysed patients, the 
clonogenicity of NKG2DLinterm cells is higher than that of corresponding NKG2DLpos, but low-




Extended Data Figure 4: Specific fluorescence intensity indices (SFI) quantitation of 
NKG2DL expression. n=55 CD34 non-expressing (a) and n=98 CD34 expressing (b) primary 
AML samples were quantified for NKG2DL expression using NKG2D-Fc chimeric protein 
staining. Shown are SFI of individual patients and subpopulations. A Mann-Whitney Test 































Extended Data Figure 5: Single ligand staining. Primary AML samples (a: n=29 CD34 non-
expressing AML; b: n=33 CD34 expressing AML) were stained with antibodies against hu-
man MICA, MICB, ULBP1 and ULBP2/5/6 and in (b) co-stained with anti-hCD34. Of note, in 
some cases the sum of % positive cells exceeds 100%, which reflects the fact that individual 
AML cells can express more than one NKG2DL. A Mann-Whitney Test was used for statisti-







Extended Data Figure 6. Co-
staining of NKG2DL with 
other LSC markers. (a) Flow 
cytometry analysis of 
NKG2DL and GPR56, CD133 
or CD96 on leukaemic cells 
distinguished by pre-gating 
with anti-human CD33-BV421. 
Shown are exemplary results 
(upper panel) and summarized 
percentages of GPR56+, CD133+ 
and CD96+ (lower panel) 
among NKG2DLneg and 
NKG2DLpos AML cells (#2, #9, 
#17, #18, #28, #31, #42, #151, 
#168; of note, 9/9 cases ex-
pressed GPR56, 8/9 CD133 and 
only 2/9 CD96). (b) Analysis of 
GPR56, CD133, CD123, CD99, 
CD25 or TIM3 among 
CD34+CD38-NKG2DLneg and 
CD34+CD38-NKG2DLpos sub-
populations. Shown are exem-
plary results (upper panel) and 
summarized data from 3 AML 
cases (#35, 37, 128; lower pan-
el); of note, another 7 AML 
(#29, 36, 38-39, 66, 95 , 101) 
were analysed but were not 
included in the analysis be-
cause all CD34+CD38- cells 
were found to lack NKG2DL 
expression. Statistical analyses 
were performed using a Mann-





Extended Data Figure 7. PARP1 protein expression in NKG2DLneg versus NKG2DLpos and 
CD34+ versus CD34- AML cells sorted from the same patient sample. Shown are immunob-
lot analyses on sorted cells; GAPDH and Actin were used as housekeeping controls. Quantifi-
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Extended Data Figure 8. Analysis of NKG2DL surface expression in CD34+ versus CD34- 
AML cells after PARPi. In vitro treatment of (a) sorted CD34+ and corresponding CD34- AML 
cells (a: schematic outline, left; representative results, middle; summarized fold changes of 
NKG2DLpos cells in AG-14361, 20 µM, versus DMSO cultured cells; #2, 27, 35) and (b) CD34 
non-expressing AML cells after PARP1 siRNA versus control siRNA (left; #9, #11, #19) and 
AG-14361 versus DMSO (right; #4, #9, #10, #11, #14, #19, #24, #75, #99, #110); shown are sum-
marized fold changes in NKG2DLpos AML cells in PARPi versus corresponding control condi-
tions. (c-d) In vivo treatment with AG-14361 (c: schematic outline; d: summarized data on 
%NKG2DLpos within CD33+, CD33+CD34+ and CD33+CD34- AML subpopulations infiltrating 
murine BM after n=5 days of in vivo treatment with AG-14361 or DMSO as vehicle control 




Extended Data Figure 9. Influence of AG-14361 on cell numbers and viability of AML cells 
and healthy cord blood derived CD34+ hematopoietic stem and progenitor cells (HSPCs). 
(a) Sorted NKG2DLpos and (b) corresponding NKG2DLneg AML cells (#16, #35, #36, #37, #151), 
as well as (c) healthy CD34+ cells from n=3 cord bloods (each analysed in technical triplicates 
of which mean values are shown) were treated with AG-14361 (20 µM) or control DMSO 
(0.2%) and afterwards analysed using DAPI for the percentage of living cells (left) and by cell 
counts for absolute cell numbers. In (d) we show the effect of in vivo treatment with AG-14361 
(d1-5, 10-15 mg/kg/day) versus DMSO (d1-5, 20%) on leukemic infiltration (% human CD33+ 
AML among murine BM cells); note that no reduction in leukemic load is observed after 5 






Extended Data Figure 10: Analysis of NKG2DL after treatment of bulk AML cells with 
AG-14361, 5-azacytidine Veliparib, ATRA and VPA. (a) Shown are quantified summarized 
fold-changes in CD34+NKG2DLpos and CD34-NKG2DLpos populations resulting after AG-
14361 (20 µM) or 5-azacytidine (5 µM) (#2, #16-18, #27, #30, #35-36, #38, #41), and respectively 
of (b) CD34+NKG2DLpos and (c) CD34-NKG2DLpos cells emerging after all-trans retinoic acid 
(ATRA, 1 µM), valproic acid (VPA, 2 µM), veliparib (10 µM), AG-14361 (20 µM), DMSO 
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Extended Data Figure 11: Comparison of NKG2DL shedding in CD34+ versus CD34- AML 
subpopulations isolated from the same patients (#16, 26, 29, 36, 40-41, 112, 118). Note that 
comparable levels of sNKG2DL were released from the two subpopulations. Mean results 
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Extended Data Figure 12: Analysis of NKG2DL mRNA expression in NKG2DLneg versus 
NKG2DLpos AML cells sorted from n=10 AML cases (#3, 10, 17, 28, 35-37, 114, 151, 168). 
Shown are relative single (a) and summarized (b) mRNA values for NKG2DL (MICA and as 
variants thereof MICA-V1, MICA-V1-1, MICB and the variants thereof MICB-V1, MICB-V2, 







































































































Extended Data Figure 13. NSG mouse xenotransplantation assays with human AML cells 
treated with AG-14361 prior to transplantation, and then co-transplanted with NK cells in 
vivo. AML cells (#27, #35, #41-43) pre-treated in vitro with AG-14361 (20uM) or DMSO (0.2%) 
were transplanted via tail vein injection into NSG mice (1x106 AML cells/mouse), which af-
terwards were co-transplanted or not with pNKC (15x106 pNKC/mouse) (n=3 mice per condi-
tion and patient). Mice were analyzed for the presence of leukaemic cells in bone marrow 
(BM), peripheral blood (PB), liver and spleen at 16h post-transplantation. Shown are (a) the 
experimental setup and (b) summarized results of n=5 independent biological experiments 
after normalization to “DMSO control without NK cells” control, which was set to 1. Statisti-
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Extended Data Figure 14. Correlations between NKG2DL surface expression and molecular 
and genetic parameters. AML with inv(16), which belong to the favourable molecular ELN 
risk group, showed significantly higher NKG2DL expression when compared to cases with-
out inv(16). All 175 patients analysed for NKG2DL expression with known genetic/molecular 
profile were included in the analyses (see respective numbers of positive/negative patients 
below each analysis; not depicted are patients with unknown result for the particular analy-




Extended Data Figure 15. Association between NKG2DL surface expression and achieve-
ment of complete remission (CR)/incomplete CR (CRi) and subsequent relapse. (a) Over-
view of included patients. (b) Left panel: Average percentage of NKG2DLpos among total 
AML cells (at diagnosis) in patients that did not achieve CR/CRi after induction therapy (left) 
versus those that did (right). Right panel: Average percentage of NKG2DLpos among total 
AML cells (at diagnosis) in patients that, after having achieved CR/CRi, subsequently main-
tained remission (left) versus those that showed relapse (right). Note that patients with initial 





Extended Data Figure 16. Association of NKG2DL surface expression and overall survival 
in patients with AML (non-APL) (a) Overview of the analysed patients. (b) Correlation be-
tween percentages of NKG2DLpos among total AML cells and overall survival. Compared 
were patients with high versus low NKG2DL expression (left panel), and patients with ≥80% 




Extended Data Figure 17. Investigation of NKG2DL surface expression on healthy hema-
topoietic cells. Shown are flow cyometry data of a) mature blood cells derived from the PB of 
n=2 healthy donors, (b) BM CD34+ and CD34+CD38- cells derived from n=5 adult healthy do-







Extended Data Figure 18. Analysis of healthy hematopoietic cells after in vivo treatment 
with AG-14361 (a) Schematic overview of the experimental procedure. (b) % NKG2DLpos vs. 
NKG2DLneg cells among total murine hematopoietic cells of specific compartments after n=5 
days of in vivo treatment with AG-14361 (20 µM) or DMSO vehicle control. (c) Absolute num-
bers of white (WBC, with distribution of neutrophils, lymphocytes and monocytes) and red 
blood cell counts (RBC) in healthy mice that received AG-14361 or DMSO (n=3 mice per 













Supplementary Data Figures  
 
 
Supplementary Figure 1. Re-transplantation assays. (a) Schematic overview of the proce-
dure. Briefly, engrafted human AML cells isolated from femora and tibiae of primarily trans-
planted mice were again sorted into NKG2DLpos and NKG2DLneg fractions and re-
transplanted intravenously into pre-irradiated secondary recipients (n=2-3 mice per group). 
Engraftment in the latter was analyzed by (b-d) flow cytometric (b: BM, c: spleen; d: PB) 
and/or (e) histopathological analysis (H&E, anti-CD33, exemplary data, #1). Note that only 

















































































































Supplementary Figure 2. Intrafemoral transplantation of NKG2DLneg and NKG2DLpos AML 
subpopulations isolated from the same AML samples. Sorted NKG2DLneg and correspond-
ing NKG2DLpos cells (#33, #34, #11, #9, #10) were transplanted at equal numbers for each AML 
case intra-femorally in pre-irradiated NSG mice (n=3-4 mice per group) and engraftment as-
sessed in murine BM 12 weeks after transplantation; shown are percentages of human leu-
kaemic among murine BM cells in mice transplanted with NKG2DLneg or NKG2DLpos sub-
populations for each AML case, each dot represents one mouse. Note that even upon trans-
plantation directly into the BM, NKG2DLpos cells failed to engraft, while corresponding 





































Supplementary Figure 3. Validation of differential gene expression by quantitative real-
time PCR. (a-b) To validate differential expression in NKG2DLneg versus NKG2DLpos sub-
populations, qRT-PCR analysis was performed on genes found up- (a) or down-regulated (b) 
in the microarray data set; shown are results of n=3 AML (#8, #6, #1), analysed each in tech-
nical triplicates; the dotted line represents gene expression in NKG2DLpos subpoulations. (c) 
qRT-PCR verification of the 17 gene stemness score; analysis was performed in the same 













































































































































































































































































































































































Supplementary Figure 4. NKG2DL expression in CD34 expressing compared to CD34 non-
expressing AML cases. (a) Waterfall plot indicating percentages of NKG2DLneg among total 
AML cells in individual patients. For comparison, see waterfall plot indicating percentages of 
NKG2DLneg cells within total AML cells in CD34 expressing AML subtypes, Figure 3b. (b) 
Quantification of percentages of NKG2DLneg cells among total AML cells in CD34 non-
expressing versus CD34 expressing AML subtypes. A Mann-Whitney U Test was performed 






































Supplementary Figure 5: Investigation of CD34+ and CD34- AML subpopulations in CFU 
and in vivo transplantation assays. (a) Representative flow cytometry analysis and (b-e) 
analysis of sorted subpopulations in CFU (b: #7, #8, #12, technical triplicates) and in vivo xen-
otransplantation assays in NSG mice (#7, #8, #12; n=5 mice per AML and subpopulation) (c: 
summarized percentages of human leukaemic among murine BM, spleen and liver cells; d: 
histopathological BM analysis using antibodies that recognize human but not mouse CD33 
and CD34, 630x; e: animal survival). A Mann-Whitney Test was performed for statistical 
analysis. Note that CD34+ subpopulations display lower percentages of NKG2DLpos cells and 







Supplementary Figure 6. PARP1 siRNA inhibition. AML cells were treated in vitro with 
individual PARP1 siRNAs, a scrambled mixture of these or scrambled non-coding PARP1 
siRNAs as control. (a-b) qRT-PCR investigating PARP1 mRNA relative to GAPDH after 24h 
of treatment (a: single PARP1 siRNA versus scrambled control, representative data from 
#151, technical triplicates; b: scrambled mixture of PARP1 siRNAs versus scrambled control 
siRNAs; dots represents averages from technical triplicates performed on each patient #16, 
#35, #38). (c-d) Flow cytometry quantification of relative CD34+NKG2DLpos and CD34-
NKG2DLneg cell percentages in cells treated with scrambled PARP1 siRNAs versus scrambled 
non-coding control siRNAs (c: representative results, #38; d: summarized data from #16, #35, 





Supplementary Figure 7. NKG2DL expression after PARPi. Patient samples were treated 
with different PARP1 siRNAs (a) or AG-14361 (b) and corresponding controls (scrambled 
control siRNA or DMSO). qRT-PCR analysis of NKG2DL and their variants (MICA, MICA-
V1, MICA-V1-1, MICB-V1, MICB-V2, MICB-V3, ULBP1-4) was performed 24h later. Shown 
are technical replicates from n=5 AML patients, as indicated. Note that heterogeneous 
NKG2DL are up-regulated upon PARPi in different AML cases. A Student’s t-test was ap-
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Supplementary Figure 8. In silico analysis of PARP1 binding to the MICA (a) and the 





Supplementary Figure 9. Correlation of NKG2DL surface expression with 
(a) age, (b) white blood cell counts and (c) blast percentages at diagnosis. 
Shown are data from 169 out of 175 patients of our cohort; excluded were 3 
patients with t(15;17) and another 3 patients in which clinical information was 
missing. 
 
 
